

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [editorial.bmjopen@bmj.com](mailto:editorial.bmjopen@bmj.com)

# BMJ Open

## NT-proBNP levels measured in health checkups during the preclinical stages of cardiac structural and functional abnormalities

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026030
Article Type:	Research
Date Submitted by the Author:	16-Aug-2018
Complete List of Authors:	Nah, Eun-Hee; Korea Association of Health Promotion, Helath promotion research institute Kim, Seong Yoon ; Korea Association of Health Promotion, Division of Cardiology, Department of Internal Medicine Cho, Seon; Korea Association of Health Promotion, Helath promotion research institute Kim, Suyoung; Korea Association of Health Promotion, Helath promotion research institute Cho, Han-Ik ; Korea Association of Health Promotion, MEDiCheck LAB
Keywords:	Heart failure < CARDIOLOGY, NT-proBNP, Echocardiography < CARDIOLOGY, Preclinical structural abnormalities, Diastolic dysfunction

SCHOLARONE™  
Manuscripts

Peer Review Only

1  
2  
3  
4 **NT-proBNP levels measured in health checkups during the preclinical stages**  
5  
6 **of cardiac structural and functional abnormalities**  
7  
8

9 Eun-Hee Nah,<sup>1</sup> Seong Yoon Kim,<sup>2</sup> Seon Cho,<sup>1</sup> Suyoung Kim,<sup>1</sup> Han-Ik Cho,<sup>3</sup>

10  
11  
12 <sup>1</sup>Department of Laboratory Medicine and Health Promotion Research Institute,  
13 Korea Association of Health Promotion, Seoul, Korea; <sup>2</sup>Division of Cardiology,  
14 Department of Internal Medicine, Korea Association of Health Promotion, Seoul,  
15 Korea; <sup>3</sup>MEDiCheck LAB, Korea Association of Health Promotion, Cheongju, Korea  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

26 Corresponding author: Eun-Hee Nah

27  
28  
29 Department of Laboratory Medicine and Health Promotion Research Institute,  
30 Korea Association of Health Promotion,  
31  
32  
33  
34 350 Hwagokro, Kangseo-Gu, Seoul 07653, Korea  
35  
36

37 Tel.: +82-2-2600-0107

38  
39  
40 Fax: +82-2-2690-4915

41 E-mail: [cellonah@hanmail.net](mailto:cellonah@hanmail.net), [cellonah@kahp.or.kr](mailto:cellonah@kahp.or.kr)  
42  
43

44  
45  
46  
47 Word counts: 1,494  
48  
49  
50  
51  
52  
53  
54

## Abstract

**Objectives:** Stage B heart failure is defined as an asymptomatic abnormality of the heart structure or function. The circulating level of N-terminal pro-B-type natriuretic peptide (NT-proBNP) is elevated in symptomatic patients with left ventricular (LV) dysfunction caused by a structural or functional abnormality. This study investigated the association of the NT-proBNP level with echocardiography detected cardiac structural or diastolic abnormalities in asymptomatic subjects with preserved LV systolic function (ejection fraction >50%).

**Methods:** We retrospectively studied 412 health examinees who underwent echocardiography and NT-proBNP test at a health-promotion center in Seoul, between January 2016 and December 2016. The left ventricular mass index, and left atrial dimension (LAD) were used as markers for structural abnormalities, and the mean  $e'$  velocity and  $E/e'$  ratio were used as markers for diastolic dysfunction. The plasma NT-proBNP level was measured using electrochemiluminescence immunoassay (DPC Immulite 2000 XPI, Siemens Healthcare Diagnostics, Tarrytown,

1  
2  
3  
4 NY, USA).  
5  
6  
7

8 **Results:** Subjects with preclinical structural abnormalities were older and had a  
9  
10 higher body mass index (BMI), higher blood pressure, lower high-density  
11 lipoprotein cholesterol level, higher NT-proBNP level, and higher E/e' ( $P<0.05$ ).  
12  
13  
14  
15  
16  
17  
18 Multivariate regression analysis indicated that the factors associated with a higher  
19  
20  
21 NT-proBNP level were being older, being female, and having a lower BMI, higher  
22  
23  
24 diastolic blood pressure, higher creatinine level, lower eGFR, and higher LAD  
25  
26  
27 ( $P<0.05$ ).  
28  
29  
30

31 **Conclusion:** The level of NT-proBNP was associated with preclinical cardiac  
32  
33  
34 structural abnormalities but not with diastolic dysfunction during asymptomatic  
35  
36  
37 health checkups.  
38  
39  
40  
41  
42  
43  
44

45 **Keywords:** Heart failure, NT-proBNP, Echocardiography, Preclinical structural  
46  
47  
48 abnormalities, Diastolic dysfunction  
49  
50  
51  
52  
53  
54

## Article Summary

The circulating level of N-terminal pro-B-type natriuretic peptide (NT-proBNP) is elevated in symptomatic patients with left ventricular (LV) dysfunction caused by a structural or functional abnormality. However, few studies have investigated the association between NT-proBNP levels and preclinical structural or functional heart abnormalities demonstrated by echocardiography performed as part of preventive screening programs in primary healthcare system. This study investigated the association of the NT-proBNP level with echocardiography-detected cardiac structural or diastolic abnormalities in asymptomatic subjects with preserved left ventricular systolic function (LVEF >50%) during health checkups. In conclusion, the level of NT-proBNP was associated with preclinical cardiac structural abnormalities but not with diastolic dysfunction during asymptomatic health checkups.

### Strengths and limitations of this study

- This is the first study to address the association of preclinical echocardiography-detected cardiac structural or diastolic abnormalities with

1  
2  
3  
4 the NT-proBNP level in a primary healthcare setting.  
5  
6  
7

- 8 ■ We suggest the optimal target subjects for screening stage B heart failure  
9

10 based on the NT-proBNP level in health checkups.  
11  
12  
13

- 14 ■ The cross-sectional study design and the relatively small sample mean that  
15  
16  
17

18 further research is needed into the associated causal relationships.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

## INTRODUCTION

Heart failure (HF) is a clinical syndrome characterized by typical symptoms and signs caused by a structural and/or functional cardiac abnormalities that result in a reduced pumping capability of heart and its pre- and post-loading volumes, stasis of blood flow, and insufficiency of the blood and oxygen supplied to the main organs [1]. The incidence of cardiovascular diseases is increasing including in younger subjects due to changes in lifestyles and dietary patterns, and there have also been increases in the rates of progression to HF [2]. Systolic dysfunction is frequently present in community-dwelling individuals without recognized symptoms of HF [3, 4]. In addition, most subjects with diastolic dysfunction have a normal left ventricular ejection fraction (LVEF), with even moderate or severe isolated diastolic dysfunction being as common as systolic dysfunction [5–7]. Thus, the early recognition and treatment of preclinical structural or functional abnormalities represent a potentially powerful strategy for reducing the incidence of HF.

N-terminal pro-B-type natriuretic peptide (NT-proBNP) is produced within



1  
2  
3  
4 myocytes and released into the circulation during increases in the ventricular and  
5  
6  
7 atrial pressures [8, 9]. The NT-proBNP level is therefore a useful diagnostic marker  
8  
9  
10 for cardiac insufficiency [10], ventricular dysfunction [11] and cardiomyopathy [12].  
11  
12  
13  
14 However, few studies have investigated the association between NT-proBNP levels  
15  
16  
17 and preclinical structural or functional heart abnormalities demonstrated by  
18  
19  
20 echocardiography performed as part of preventive screening programs in primary  
21  
22  
23 healthcare system.  
24

25  
26  
27 This study investigated the association of the NT-proBNP level with  
28  
29  
30 echocardiography-detected cardiac structural or diastolic abnormalities in  
31  
32  
33 asymptomatic subjects with preserved left ventricular systolic function (LVEF  
34  
35  
36 >50%) during health checkups.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

## METHODS

### Subjects

We retrospectively studied 412 health examinees who underwent echocardiography and NT-proBNP test during health checkups at a health-promotion center in Seoul between January 2016 and December 2016. The self-reported personal medical history, subjective symptoms and signs, and life style information were obtained from all participants at time of health checkups. Their medical records were also reviewed. Participants who had valvular heart disease, acute myocardial infarction, stroke, renal dysfunction, LVEF < 50%, or clinical symptoms or signs of HF were excluded from this study.

This study was approved by the Institutional Review Board of Korea Association of Health Promotion (approval no. 130750-201807-HR-016).

### Echocardiography

The echocardiographic investigations were carried out using a Philips/Hewlett-Packard Sono 5500 ultrasound device (Philips Ultrasound, Andover, MA, USA). M-

1  
2  
3  
4 mode, two-dimensional, and hemodynamic Doppler images were acquired using  
5  
6  
7 a standardized protocol with a 3.5-MHZ transducer. LVEF was calculated using the  
8  
9  
10 modified Simpson method. An increased left ventricular mass index (LVMI; >115  
11  
12  
13 g/m<sup>2</sup> in males and >95 g/m<sup>2</sup> in females), and an increased left atrial dimension  
14  
15  
16 (LAD; >41 mm in males and >39 mm in females) were used as markers for  
17  
18  
19 structural abnormalities [13]. The diastolic function was evaluated using the early  
20  
21  
22 diastolic mitral flow velocity (E), early relaxation velocity in tissue Doppler  
23  
24  
25 recordings (e') and the E/e' ratio. E/e' ≥13 and a mean e' septal and lateral wall  
26  
27  
28 velocity of <9 cm/s were used as markers for diastolic dysfunction [14].  
29  
30  
31  
32  
33

#### 34 **NT-proBNP measurement**

35  
36  
37 Venous blood was collected in an lithium-heparin tube. The plasma NT-proBNP  
38  
39  
40 level was measured using an electrochemiluminiscent immunoassay on a DPC  
41  
42  
43 Immulite 2000 XPi device (Siemens Healthcare Diagnostics, Tarrytown, NY, USA).  
44  
45  
46  
47 The intra-assay and total variances were 3.4% and 4.7%, respectively, and the limit  
48  
49  
50 of detection was 10 pg/mL.  
51  
52  
53  
54

## Statistical analysis

Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA). Differences in the characteristics of the study subjects between with and without structural abnormalities and between with and without diastolic dysfunction were analyzed using Student's *t*-test or the chi-square test. Univariate and multivariate regression analyses were performed to determine the variables affecting an increased NT-proBNP level. Wilcoxon rank sum tests were performed to compare mean NT-proBNP levels between sexes, and between with and without structural abnormalities in each age groups, respectively. A *P* value of <0.05 was considered statistically significant.

## Patient and public involvement

Patients were not involved in the recruitment to and conduct of the study. Results will be disseminated to study participants through annual information events.

## RESULTS

This study enrolled 412 participants with a median age of 58 years (range 28–82 years). Echocardiography revealed structural abnormalities in 60 (14.6%) of the subjects, who were older ( $60.3 \pm 8.5$  vs  $57.2 \pm 9.3$  years [mean  $\pm$  SD],  $P < 0.017$ ), and had a higher body mass index (BMI), higher blood pressure, lower high-density lipoprotein cholesterol (HDL-C) level, higher NT-proBNP level ( $65.6 \pm 109.7$  vs  $29.8 \pm 28.7$  pg/mL,  $P = 0.015$ ), and higher E/e' ratio ( $12.5 \pm 2.9$  vs  $11.1 \pm 3.3$ ) in echocardiography (Table 1).

Diastolic dysfunction was detected using echocardiography in 283 (68.7%) of the subjects. These subjects were older and had a higher BMI, higher blood pressure, higher hemoglobin, higher triglycerides, and lower HDL-C levels. However, the NT-proBNP level did not differ significantly between subjects with and without diastolic dysfunction (Table 2).

In a multivariate model, being older, being female, and having a lower BMI, higher diastolic blood pressure, higher creatinine level, higher eGFR level and

1  
2  
3  
4 higher LAD were associated with an increased NT-proBNP level ( $P<0.05$ ). While  
5  
6  
7 sex was not associated with the NT-proBNP level in a univariate model, being  
8  
9  
10 female was associated with increased NT-proBNP level ( $P<0.01$ ) in multivariate  
11  
12  
13 model (Table 3). Among subjects younger than 61 years (combining those aged  
14  
15  
16  $\leq 45$  and 46–60 years), females showed higher NT-proBNP levels than males,  
17  
18  
19 while there was no significant difference between males and females among  
20  
21  
22 those aged  $\geq 61$  years (Figure 1). A structural abnormality defined by a higher  
23  
24  
25 LAD was associated with an increased NT-proBNP level ( $P<0.01$ ) but the E/e' ratio  
26  
27  
28 and mean e' velocity were not associated with NT-proBNP. In subjects aged 46–60,  
29  
30  
31 and  $\geq 61$  years, those with structural abnormality showed a higher NT-proBNP  
32  
33  
34 level ( $P=0.014$  and  $P=0.001$ , respectively) (Figure 2).  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## DISCUSSION

This study investigated the association between NT-proBNP levels with echocardiography-detected cardiac structural abnormalities and diastolic dysfunction in asymptomatic subjects with preserved left ventricular systolic function in a primary healthcare setting. Subjects with structural abnormalities that were not yet apparent, were older and had a higher BMI, higher blood pressure, lower HDL-C level, or greater impairment of diastolic function in echocardiography. Furthermore, we have demonstrated that NT-proBNP levels are associated with preclinical cardiac structural abnormalities but not with diastolic dysfunction.

We observed associations of diastolic dysfunction with cardiovascular risk factors such as higher BMI, blood pressure, blood glucose, and triglycerides, and lower HDL-C levels. These results are consistent with reports of the presence of diastolic dysfunction being closely associated with cardiovascular diseases [15–17]]. Furthermore, subjects with diastolic dysfunction exhibited elevated LVMI and LAD,

1  
2  
3  
4 which indicate the presence of structural abnormalities. These findings support  
5  
6  
7 that a hypertrophied ventricle is more likely to exhibit diastolic dysfunction and a  
8  
9  
10 chronic increase in the left atrial pressure associated with diastolic dysfunction,  
11  
12  
13 and would be expected to lead to atrial enlargement [18].  
14  
15

16  
17 NT-proBNP is released into the circulation in response to a stretched  
18  
19 myocardium resulting from any cardiac structural abnormalities [19]. Hung et al.  
20  
21 [20] demonstrated an association between any structural anomaly and NT-  
22  
23 proBNP levels, which was consistent with our finding of the NT-proBNP level  
24  
25 being associated with subclinical cardiac structural abnormalities. This means that  
26  
27 an elevated circulating level of NT-proBNP is a predictor of systolic dysfunction.  
28  
29  
30 However, we found no association between preclinical diastolic dysfunction (PDD)  
31  
32 and the circulating NT-proBNP level. These differences might be due to  
33  
34 differences between the included subjects: our study subjects participated in  
35  
36 routine health checkups and preexcluded any valvular heart disease or pulmonary  
37  
38 hypertension, while the subjects included in the previous study had aortic root  
39  
40 dilatation, ventricular hypertrophy, pulmonary hypertension or valvular heart  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54



1  
2  
3  
4 disease and presented at a tertiary referral center. Another previous study of PDD  
5  
6  
7 [21] found that while advanced diastolic dysfunction with a normal LVEF was  
8  
9  
10 independently associated with structural abnormalities (increased LVMI and left  
11  
12  
13 atrial volume index [LAVI]) and increased circulating NT-proBNP, the structural  
14  
15  
16 abnormalities and NT-proBNP levels did not differ between normal controls and  
17  
18  
19 patients with mild diastolic dysfunction.  
20  
21  
22  
23

24 Among subjects with a normal LVEF and no HF diagnosis, a higher severity of  
25  
26  
27 diastolic dysfunction was associated with a higher mean LVMI and LAVI [18]. Our  
28  
29  
30 subjects with diastolic dysfunction had relatively low mean LVMI or LAD values,  
31  
32  
33 and they are therefore likely to have had only mild diastolic dysfunction. Our  
34  
35  
36 observations suggest that the association between PDD and circulating NT-  
37  
38  
39 proBNP levels may vary according to the severity of diastolic dysfunction.  
40  
41  
42  
43 Therefore, the screening of preclinical structural or functional abnormalities based  
44  
45  
46 on NT-proBNP levels could be optimized by targeting subjects with potentially  
47  
48  
49 advanced diastolic dysfunction, which encompasses those who are older and have  
50  
51  
52 cardiovascular risk factors such as obesity, hypertension, higher blood glucose or  
53  
54  
55

1  
2  
3  
4 dyslipidemia in health checkups.  
5  
6  
7

8 Our study have some limitations. Its cross-sectional design and relatively small  
9  
10 sample mean that further research is needed into the associated causal  
11  
12 relationships. Data on potential clinical correlates of diastolic dysfunction such as  
13  
14 exercise tolerance were not included. Moreover, the echocardiographic  
15  
16 evaluation was performed using a minimal data set that did not include detailed  
17  
18 echocardiographic data on diastolic function.  
19  
20  
21  
22  
23  
24  
25  
26  
27

28 In conclusion, the findings of this study suggest that NT-proBNP levels are  
29  
30 associated with preclinical cardiac structural abnormalities but not with diastolic  
31  
32 dysfunction, which is applicable to stage-B HF from among the four categories  
33  
34 defined by the American Ccollege of Cardiology and American Heart Association.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 **Figure 1.** N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels according  
46  
47 to sex and age categories. Box limits and horizontal lines within boxes represent  
48  
49 interquartile ranges and the median, respectively. The upper and lower whiskers  
50  
51 indicate the 97.5th and 2.5th percentiles, respectively.  
52  
53  
54

1  
2  
3  
4 **Figure 2.** N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels of subjects  
5 with and without structural abnormalities according to age categories. Box limits  
6 and horizontal lines within boxes represent interquartile ranges and the median,  
7 respectively. The upper and lower whiskers indicate the 97.5th and 2.5th  
8 percentiles, respectively.  
9  
10  
11  
12  
13  
14

15 **Acknowledgements** The authors would like to thank the participants who made  
16 this study possible.  
17  
18  
19  
20  
21

22 **Author Contributions** All of the authors participated in designing this study. SC  
23 and SYK performed data collection. SK undertook the statistical analyses. EN, SYK,  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

39 **Funding** This research received no specific grant from any funding agency in the  
40 public or commercial sectors.  
41  
42  
43  
44  
45

46 **Competing interests** None to declare.  
47  
48  
49

50 **Patient consent** Obtained.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 **Ethics approval** This study was approved by the Institutional Review Board of the  
5  
6  
7 Korea Association of Health Promotion (approval no. 130750-201807-HR-016).  
8  
9

10  
11 **Provenance and peer review** Not commissioned; externally peer reviewed.  
12  
13

14  
15 **Data sharing statement** No additional data are available.  
16  
17

18  
19 **Open access**  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

## REFERENCES

1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2016;37:2129–200.
2. Felker GM, Anstrom KJ, Adams KF, et al. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. *JAMA* 2017;318:713–20.
3. Davies M, Hobbs F, Davis R, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. *Lancet* 2001;358:439–44.
4. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart failure and left

- 1  
2  
3  
4 ventricular dysfunction in the general population; The Rotterdam Study. *Eur*  
5  
6  
7 *Heart J* 1999;20:447–55.  
8  
9
- 10  
11 5. Mureddu GF, Agabiti N, Rizzello V, et al. Prevalence of preclinical and clinical  
12  
13 heart failure in the elderly. A population-based study in Central Italy. *Eur J*  
14  
15  
16 *Heart Fail* 2012;14:718–29.  
17  
18
- 19  
20 6. Fischer M, Baessler A, Hense HW, et al. Prevalence of left ventricular diastolic  
21  
22  
23 dysfunction in the community: Results from a Doppler echocardiographic-  
24  
25  
26 based survey of a population sample. *Eur Heart J* 2003;24:320–8.  
27  
28  
29
- 30 7. Kuznetsova T, Herbots L, López B, et al. Prevalence of left ventricular diastolic  
31  
32  
33 dysfunction in a general population. *Circ Heart Fail* 2009;2:105–12.  
34  
35  
36
- 37 8. Yu J, Oh PC, Kim M, et al. Improved early risk stratification of patients with ST-  
38  
39  
40 segment elevation myocardial infarction undergoing primary percutaneous  
41  
42  
43 coronary intervention using a combination of serum soluble ST2 and NT-  
44  
45  
46 proBNP. *PLoS One* 2017;12:e0182829.  
47  
48
- 49 9. Hall C. Essential biochemistry and physiology of (NT-pro) BNP. *Eur J Heart Fail*  
50  
51  
52 2004;6:257–60.  
53  
54

- 1  
2  
3  
4 10. Coats CJ, Parisi V, Ramos M, et al. Role of serum N-terminal pro-brain  
5  
6  
7 natriuretic peptide measurement in diagnosis of cardiac involvement in  
8  
9  
10 patients with Anderson-Fabry disease. *Am J Cardiol* 2013;111:111–7.  
11  
12
- 13  
14 11. Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart  
15  
16  
17 failure: a consensus statement on the diagnosis of heart failure with normal  
18  
19  
20 left ventricular ejection fraction by the Heart Failure and Echocardiography  
21  
22  
23 Associations of the European Society of Cardiology. *Eur Heart J* 2007;28:2539–  
24  
25  
26 50.  
27  
28  
29
- 30 12. Gehle P, Robinson PN, Heinzl F, et al. NT-proBNP and diastolic left ventricular  
31  
32  
33 function in patients with Marfan syndrome. *Int J Cardiol Heart Vasc*  
34  
35  
36 2016;12:15–20.  
37  
38  
39
- 40 13. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber  
41  
42  
43 quantification by echocardiography in adults: an update from the American  
44  
45  
46 Society of Echocardiography and the European Association of Cardiovascular  
47  
48  
49 Imaging. *Eur Heart J Cardiovasc Imaging* 2015;16:233–71.  
50  
51  
52
- 53 14. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the  
54  
55  
56

1  
2  
3  
4 evaluation of left ventricular diastolic function by echocardiography: an update  
5  
6  
7 from the American Society of Echocardiography and the European Association  
8  
9  
10 of Cardiovascular Imaging. *J Am Soc Echocardiogr* 2016;29:277–314.

11  
12  
13  
14 15. Kane GC, Karon BL, Mahoney DW, et al. Progression of left ventricular diastolic  
15  
16  
17 dysfunction and risk of heart failure. *JAMA* 2011;306:856–63.

18  
19  
20 21. From AM, Scott CG, Chen HH. The development of heart failure in patients  
21  
22  
23 with diabetes mellitus and pre-clinical diastolic dysfunction: a population-  
24  
25  
26 based study. *J Am Coll Cardiol* 2010;55:300–5.

27  
28  
29  
30 31. Ren X, Ristow B, Na B, et al. Prevalence and prognosis of asymptomatic left  
31  
32  
33 ventricular diastolic dysfunction in ambulatory patients with coronary heart  
34  
35  
36 disease. *Am J Cardiol* 2007;99:1643–7.

37  
38  
39  
40 41. Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and diastolic  
41  
42  
43 ventricular dysfunction in the community: appreciating the scope of the heart  
44  
45  
46 failure epidemic. *JAMA* 2003;289:194–202.

47  
48  
49  
50 51. Mueller T, Gegenhuber A, Poelz W, et al. Comparison of the Biomedica NT-  
51  
52  
53 proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence  
54



1  
2  
3  
4 immunoassay: implications for the prediction of symptomatic and  
5  
6  
7 asymptomatic structural heart disease. *Clin Chem* 2003;49:976–9.  
8  
9

10  
11 20. Hung TC, Wang KT, Yun CH, et al. Value of serum N-terminal B-type natriuretic  
12  
13 peptide in asymptomatic structural heart disease in Taiwanese population:  
14  
15 Comparisons with current ESC Guidelines. *Int J Cardiol* 2017;231:195–200.  
16  
17  
18

19  
20 21. Abhayaratna WP, Marwick TH, Smith WT, et al. Characteristics of left  
21  
22 ventricular diastolic dysfunction in the community: an echocardiographic  
23  
24 survey. *Heart* 2006;92:1259–64.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

Table 1 Characteristics of study subjects according to the presence of structural abnormalities

Variable	No structural abnormalities	Structural abnormalities	<i>P</i>
	(N=352)	(N=60)	
Age years	57.2±9.3	60.3±8.5	0.017
Sex, male, N (%)	192 (54.5)	36 (60.0)	0.432
BMI (kg/m <sup>2</sup> )	24.2±3.2	26.5±2.7	0.000
SBP (mmHg)	118.9±13.6	125.9±11.1	0.000
DBP (mmHg)	72.3±8.8	76.4±8.7	0.003
Hemoglobin (g/L)	147±15	148±18	0.965
FBS (mmol/L)	5.96±1.43	6.17±1.60	0.289
TC (mmol/L)	5.45±1.09	5.21±0.97	0.110
TG (mmol/L)	1.33±0.93	1.59±1.19	0.125
HDL-C (mmol/L)	1.51±0.40	1.35±0.29	0.000
LDL-C (mmol/L)	3.33±1.03	3.16±1.00	0.236
Creatinine (µmol/L)	76.02±13.97	77.79±15.56	0.520
eGFR (mL/min/1.73m <sup>2</sup> )	87.5±13.6	86.6±14.2	0.639
NT-proBNP (pg/mL)	29.8±28.7	65.6±109.7	0.015
LVEF (%)	66.9±6.4	67.1±6.0	0.807
LVM <sub>VI</sub> (g/m <sup>2</sup> )	72.2±13.9	89.5±15.4	0.000
LAD (mm)	33.8±3.8	40.9±6.0	0.000
E/e'	11.1±3.3	12.5±2.9	0.002
e' (cm/s)	6.4±1.6	6.4±6.6	0.950

Continuous variables are expressed as mean±SD values and were compared using Student's *t*-test. Categorical variables are expressed as N (%) values and were analyzed using the chi-square test. NT-proBNP, N-terminal pro-B-type natriuretic peptide; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglyceride; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; FBS, fasting blood sugar; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; LAD, left atrial dimension; E/e', early diastolic mitral inflow velocity/early diastolic mitral annular velocity; e', mean e' septal and lateral wall velocity.

Table 2. Characteristics of study subjects according to the presence of diastolic dysfunction

Variables	No diastolic dysfunction	Diastolic dysfunction	<i>P</i>
	(N=129)	(N=283)	
Age (year)	53.1±9.4	59.7±8.4	0.000
Sex, male, N (%)	68 (52.7)	160 (56.5)	0.469
BMI (kg/m <sup>2</sup> )	23.3±3.1	25.1±3.1	0.000
SBP (mmHg)	115.6±12.2	121.9±13.6	0.000
DBP (mmHg)	70.4±8.1	74.6±8.9	0.000
Hemoglobin (g/L)	144±17	149±15	0.002
FBS (mmol/L)	5.68±1.12	6.13±1.57	0.001
TC (mmol/L)	5.35±1.06	5.44±1.08	0.452
TG (mmol/L)	1.18±0.83	1.46±1.03	0.004
HDL-C (mmol/L)	1.56±0.40	1.45±0.38	0.007
LDL-C (mmol/L)	3.25±0.98	3.33±1.05	0.499
Creatinine (μmol/L)	76.02±14.85	76.91±13.88	0.544
eGFR (mL/min/1.73m <sup>2</sup> )	89.2±14.7	86.5±13.1	0.063
NT-proBNP (pg/mL)	38.8±73.6	33.3±36.1	0.306
LVEF (%)	66.1±6.6	67.3±6.2	0.081
LVMI (g/m <sup>2</sup> )	70.2±14.7	76.8±15.3	0.000
LAD (mm)	34.1±5.3	35.2±4.7	0.040
E/e'	9.4±2.2	12.1±3.3	0.000
e' (cm/s)	8.5±4.3	5.4±1.0	0.000

Continuous variables are expressed as mean±SD values and were compared using Student's *t*-test. Categorical variables are expressed as N (%) values and were analyzed using the chi-square test. NT-proBNP, N-terminal pro-B-type natriuretic peptide; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglyceride; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; FBS, fasting blood sugar; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; LAD, left atrial dimension; E/e', early diastolic mitral inflow velocity/early diastolic mitral annular velocity; e', mean e' septal and lateral wall velocity.

Table 3. Regression analysis of the variables affecting an increased NT-proBNP level

Variables	Univariate model	Multivariate model
Age (year)	0.202**	0.303**
Sex, male	-0.043	0.980**
BMI (kg/m <sup>2</sup> )	-0.009	-0.154**
SBP (mmHg)	0.026	-0.144*
DBP (mmHg)	0.066	0.167*
Hb (g/L)	0.001	-0.043
FBS (mmol/L)	-0.080	-0.048
TC (mmol/L)	-0.111*	0.789
TG (mmol/L)	-0.056	-0.369
HDL-C (mmol/L)	-0.046	-0.310
LDL-C (mmol/L)	-0.075	-0.825
Creatinine (µmol/L)	0.219**	1.411**
eGFR (mL/min/1.73m <sup>2</sup> )	-0.240**	0.814**
LVEF (%)	-0.002	0.012
LVMI (g/m <sup>2</sup> )	0.167**	0.086
LAD (mm)	0.298**	0.341**
E/e'	0.017	-0.039
e' (cm/s)	-0.021	0.015

1  
2  
3  
4 Model significance; \* P<0.05, \*\* P<0.01

5 NT-proBNP, N-terminal pro-B-type natriuretic peptide; BMI, body mass index; SBP, systolic blood  
6 pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglyceride; HDL-C, HDL-  
7 cholesterol; LDL-C, LDL-cholesterol; FBS, fasting blood sugar; LVEF, left ventricular ejection fraction;  
8 LVMI, left ventricular mass index; LAD, left atrial dimension; E/e', early diastolic mitral inflow  
9 velocity/early diastolic mitral annular velocity; e', mean e' septal and lateral wall velocity.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

For peer review only




Figure 1 N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels according to sex and age categories. Box limits and horizontal lines within boxes represent interquartile ranges and the median, respectively. The upper and lower whiskers indicate the 97.5th and 2.5th percentiles, respectively.

Figure 1 N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels according to sex and age categories. Box limits and horizontal lines within boxes represent interquartile ranges and the median, respectively. The upper and lower whiskers indicate the 97.5th and 2.5th percentiles, respectively.

269x246mm (96 x 96 DPI)




Figure 2 N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels of subjects with and without structural abnormalities according to age categories. Box limits and horizontal lines within boxes represent interquartile ranges and the median, respectively. The upper and lower whiskers indicate the 97.5th and 2.5th percentiles, respectively.

Figure 2 N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels of subjects with and without structural abnormalities according to age categories. Box limits and horizontal lines within boxes represent interquartile ranges and the median, respectively. The upper and lower whiskers indicate the 97.5th and 2.5th percentiles, respectively.

277x246mm (96 x 96 DPI)

# BMJ Open

## NT-proBNP levels measured in health checkups with preserved ejection fraction during the preclinical stages of cardiac structural and functional abnormalities: a retrospective and cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026030.R1
Article Type:	Research
Date Submitted by the Author:	31-Dec-2018
Complete List of Authors:	Nah, Eun-Hee; Korea Association of Health Promotion, Helath promotion research institute Kim, Seong Yoon ; Korea Association of Health Promotion, Division of Cardiology, Department of Internal Medicine Cho, Seon; Korea Association of Health Promotion, Helath promotion research institute Kim, Suyoung; Korea Association of Health Promotion, Helath promotion research institute Cho, Han-Ik ; Korea Association of Health Promotion, MEDiCheck LAB
<b>Primary Subject Heading</b>:	Cardiovascular medicine
Secondary Subject Heading:	Diagnostics
Keywords:	Heart failure < CARDIOLOGY, NT-proBNP, Echocardiography < CARDIOLOGY, Preclinical structural abnormalities, Diastolic dysfunction

SCHOLARONE™  
Manuscripts



1  
2  
3  
4 1 **NT-proBNP levels measured in health checkups with preserved ejection**  
5  
6 2 **fraction during the preclinical stages of cardiac structural and functional**  
7  
8 3 **abnormalities: a retrospective and cross-sectional study**  
9  
10  
11 4

12  
13 5 Eun-Hee Nah,<sup>1</sup> Seong Yoon Kim,<sup>2</sup> Seon Cho,<sup>1</sup> Suyoung Kim,<sup>1</sup> Han-Ik Cho,<sup>3</sup>

14  
15  
16 6 <sup>1</sup>Department of Laboratory Medicine and Health Promotion Research Institute, Korea  
17 7 Association of Health Promotion, Seoul, Korea; <sup>2</sup>Division of Cardiology, Department of  
18 8 Internal Medicine, Korea Association of Health Promotion, Seoul, Korea; <sup>3</sup>MEDiCheck LAB,  
19 9 Korea Association of Health Promotion, Cheongju, Korea  
20  
21  
22

23  
24  
25  
26 11 Corresponding author: Eun-Hee Nah

27  
28 12 Department of Laboratory Medicine and Health Promotion Research Institute, Korea  
29 13 Association of Health Promotion,  
30  
31  
32 14 350 Hwagokro, Kangseo-Gu, Seoul 07653, Korea

33  
34  
35 15 Tel.: +82-2-2600-0107

36  
37 16 Fax: +82-2-2690-4915

38  
39 17 E-mail: [cellonah@hanmail.net](mailto:cellonah@hanmail.net), [cellonah@kahp.or.kr](mailto:cellonah@kahp.or.kr)

40  
41  
42 18 Word counts: 1,494  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 **1 ABSTRACT**  
5

6  
7 **2 Objectives:** Stage B heart failure is defined as an asymptomatic abnormality of the heart  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
**3** structure or function. The circulating level of N-terminal pro-B-type natriuretic peptide (NT-  
**4** proBNP) is elevated in symptomatic patients with left ventricular (LV) dysfunction caused by  
**5** a structural or functional abnormality. This study investigated the association of the NT-  
**6** proBNP level with echocardiography detected cardiac structural or diastolic abnormalities in  
**7** asymptomatic subjects with preserved LV systolic function (ejection fraction >50%).

**8** **Methods:** We retrospectively studied 652 health examinees who underwent echocardiography  
**9** and NT-proBNP test at a health-promotion center in Seoul, between January 2016 and  
**10** September 2018. The left ventricular mass index (LVMI), and left atrial dimension (LAD) were  
**11** used as markers for structural abnormalities, and the mean e' velocity and E/e' ratio were used  
**12** as markers for diastolic dysfunction. The plasma NT-proBNP level was measured using  
**13** electrochemiluminescence immunoassay (DPC Immulite 2000 XPi, Siemens Healthcare  
**14** Diagnostics, Tarrytown, NY, USA).

**15** **Results:** Subjects with preclinical structural abnormalities were older and had a higher body  
**16** mass index (BMI), higher blood pressure, lower high-density lipoprotein cholesterol level,  
**17** higher NT-proBNP level, and higher E/e' ( $P<0.05$ ). Multivariate regression analysis indicated  
**18** that the factors associated with a higher NT-proBNP level were being older, being female, and  
**19** having a lower BMI, higher creatinine level, higher LVMI and higher LAD ( $P<0.01$ ).

**20** **Conclusion:** The level of NT-proBNP was associated with preclinical cardiac structural  
**21** abnormalities but not with diastolic dysfunction during asymptomatic health checkups.  
**22**

1  
2  
3  
4 1 **Keywords:** Heart failure, NT-proBNP, Echocardiography, Preclinical structural abnormalities,  
5  
6 2 Diastolic dysfunction  
7  
8  
9

10 3

11 4 **Strengths and limitations of this study**

- 12  
13 5 ■ This is the first study to address the association of early stage of preclinical  
14  
15 6 echocardiography-detected cardiac structural or diastolic abnormalities with the NT-  
16  
17 7 proBNP level in a primary healthcare setting.  
18  
19  
20  
21 8 ■ We suggest the optimal target subjects with potentially cardiac structural abnormality,  
22  
23 9 which encompasses those who are older and have cardiovascular risk factors such as  
24  
25 10 obesity, hypertension, or dyslipidemia for screening early stage B heart failure based on  
26  
27 11 the NT-proBNP level in health checkups.  
28  
29  
30  
31 12 ■ The cross-sectional study design and the relatively small sample mean that further  
32  
33 13 research is needed into the associated causal relationships.  
34  
35  
36 14  
37  
38  
39 15  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 INTRODUCTION

2 Heart failure (HF) is a clinical syndrome characterized by typical symptoms and signs caused  
3 by a structural and/or functional cardiac abnormalities that result in a reduced pumping  
4 capability of heart and its pre- and post-loading volumes, stasis of blood flow, and insufficiency  
5 of the blood and oxygen supplied to the main organs [1]. The incidence of cardiovascular  
6 diseases is increasing including in younger subjects due to changes in lifestyles and dietary  
7 patterns, and there have also been increases in the rates of progression to HF [2]. Systolic  
8 dysfunction is frequently present in community-dwelling individuals without recognized  
9 symptoms of HF [3, 4]. In addition, most subjects with diastolic dysfunction have a normal left  
10 ventricular ejection fraction (LVEF), with even moderate or severe isolated diastolic  
11 dysfunction being as common as systolic dysfunction [5–7]. Thus, the early recognition and  
12 treatment of preclinical structural or functional abnormalities represent a potentially powerful  
13 strategy for reducing the incidence of HF.

14 N-terminal pro-B-type natriuretic peptide (NT-proBNP) is produced within myocytes and  
15 released into the circulation during increases in the ventricular and atrial pressures [8, 9]. The  
16 NT-proBNP level is therefore a useful diagnostic marker for cardiac insufficiency [10],  
17 ventricular dysfunction [11] and cardiomyopathy [12]. However, few studies have investigated  
18 the association between NT-proBNP levels and early stage of preclinical structural or  
19 functional heart abnormalities demonstrated by echocardiography performed as part of  
20 preventive screening programs in primary healthcare system.

21 This study investigated the association of the NT-proBNP level with echocardiography-  
22 detected early stage of cardiac structural or diastolic abnormalities in asymptomatic subjects  
23 with preserved left ventricular systolic function (LVEF >50%) during health checkups.

## 1       2       3 4       1    **METHODS**

### 5       6       7       8 9       2    **Subjects**

10       3    We retrospectively studied consecutive health examinees aged over 18-year old who underwent  
11       4    echocardiography and NT-proBNP test during health checkups at a health-promotion center in  
12       5    Seoul between January 2016 and September 2018. The study design was retrospective and  
13       6    cross-sectional. The self-reported personal medical history, subjective symptoms and signs,  
14       7    and life style information were obtained from all participants at time of health checkups. Their  
15       8    medical records were also reviewed. Our study subjects had no previous cardiac surgery or  
16       9    diagnosed heart disease and they presented with preserved left ventricular systolic function  
17       10   (LVEF>50%) determined by echocardiography. Subjects who had echocardiography-detected  
18       11   valvular heart disease, atrial fibrillation, acute myocardial infarction, stroke, renal dysfunction,  
19       12   pregnancy, echocardiography-detected LVEF < 50%, or clinical symptoms or signs of HF were  
20       13   excluded from this study. After exclusion, the final sample size was 652 (361 males and 291  
21       14   females: aged 28–82)

22       15    This study was approved by the Institutional Review Board of Korea Association of Health  
23       16    Promotion (approval no. 130750-201807-HR-016).

### 24       17    **Echocardiography**

25       18    The echocardiographic investigations were carried out using a Philips/Hewlett-Packard Sono  
26       19    5500 ultrasound device (Philips Ultrasound, Andover, MA, USA). M-mode, two-dimensional,  
27       20    and hemodynamic Doppler images were acquired using a standardized protocol with a 3.5-  
28       21    MHZ transducer. LVEF was calculated using the modified Simpson method [13]. An increased  
29       22    left ventricular mass index (LVMI; >115 g/m<sup>2</sup> in males and >95 g/m<sup>2</sup> in females), and an

1  
2  
3  
4 1 increased left atrial dimension (LAD; >41 mm in males and >39 mm in females) were used as  
5  
6 2 markers for structural abnormalities [14]. The diastolic function was evaluated using the early  
7  
8 3 diastolic mitral flow velocity (E), early relaxation velocity in tissue Doppler recordings (e')  
9  
10 4 and the E/e' ratio. E/e'  $\geq$ 13, and a mean e' septal and lateral wall velocity of <9 cm/s were used  
11  
12 5 as markers for diastolic dysfunction [15]. Structural cardiac abnormality was defined as the  
13  
14 6 increased LVMI (LVMI; >115 g/m<sup>2</sup> in males and >95 g/m<sup>2</sup> in females) and/or increased LAD  
15  
16 7 (LAD; >41 mm in males and >39 mm in females). Cardiac diastolic dysfunction was defined  
17  
18 8 as an E/e'  $\geq$ 13 and/or a mean e' septal and lateral wall <9 cm/s.  
19  
20  
21  
22

### 23 9 **NT-proBNP measurement**

24  
25  
26 10 Venous blood was collected in an lithium-heparin tube. The plasma NT-proBNP level was  
27  
28 11 measured using an electrochemiluminescent immunoassay on a DPC Immulite 2000 XPi  
29  
30 12 device (Siemens Healthcare Diagnostics, Tarrytown, NY, USA). The intra-assay and total  
31  
32 13 variances were 3.4% and 4.7%, respectively, and the limit of detection was 10 pg/mL.  
33  
34  
35

### 36 14 **Statistical analysis**

37  
38  
39 15 Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA).  
40  
41 16 Differences in the characteristics of the study subjects were analyzed according to the presence  
42  
43 17 of structural abnormalities using Student's *t*-test or the chi-square test. In addition, differences  
44  
45 18 in the characteristics of the study subjects were analyzed according to the presence of diastolic  
46  
47 19 dysfunction using Student's *t*-test or the chi-square test. Among those with one of structural  
48  
49 20 abnormality or diastolic dysfunction or both abnormality, differences in the characteristics of  
50  
51 21 the study subjects were analyzed using ANOVA. Univariate (crude) and multivariate (adjusted)  
52  
53 22 regression analyses were performed to determine the variables affecting an increased NT-  
54  
55 23 proBNP level. Variables considered in the analysis included age, sex, body mass index (BMI),  
56  
57  
58  
59  
60

1  
2  
3  
4 1 systolic blood pressure, diastolic blood pressure, hemoglobin, fasting blood glucose,  
5  
6 2 triglyceride, HDL-cholesterol, LDL-cholesterol, creatinine, LVEF, LVMI, LAD, E/e' and e'.  
7  
8  
9 3 We used multiple linear regression model to control for effects of included age, sex, BMI, blood  
10  
11 4 pressure, Hb, FBS, blood lipid, creatinine, LVEF, LVMI, LAD, E/e' and e' (Model 1). Additional  
12  
13 5 regression model adjusted for age, sex, BMI, creatinine, LVMI, and LAD was used to identify  
14  
15 6 increased NT-proBNP level in multivariate model (Model 2). Wilcoxon rank sum tests were  
16  
17 7 performed to compare mean NT-proBNP levels between sexes, and between with and without  
18  
19 8 structural abnormalities in each age groups, respectively. In addition, Wilcoxon rank sum test  
20  
21 9 was used to compare those with diastolic dysfunction to those without diastolic dysfunction.  
22  
23 10 Logarithmic transformations were applied to NT-proBNP level. Area under the receiver  
24  
25 11 operating curve (AUROC) was calculated to measure the performance of NT-proBNP in  
26  
27 12 predicting the cardiac structural abnormalities. A *P* value of <0.05 was considered statistically  
28  
29 13 significant.  
30  
31  
32  
33  
34

#### 35 14 **Patient and public involvement**

36  
37  
38 15 Patients were not involved in the recruitment to and conduct of the study. Results will be  
39  
40 16 disseminated to study participants through annual information events.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 RESULTS

2 There were a total of 652 study subjects with a median age of 58 years (range 28–82 years).  
3 Echocardiography revealed structural abnormalities in 92 (14.1%) of the subjects, who were  
4 older ( $60.8 \pm 8.8$  vs  $57.7 \pm 8.9$  years [mean $\pm$ SD],  $P < 0.017$ ), and had a higher body mass index  
5 (BMI), higher blood pressure, lower high-density lipoprotein cholesterol (HDL-C) level.  
6 higher NT-proBNP level ( $55.8 \pm 91.5$  vs  $29.6 \pm 27.5$  pg/mL,  $P = 0.015$ ), and higher E/e' ratio  
7 ( $13.0 \pm 3.5$  vs  $11.0 \pm 3.4$ ) in echocardiography (Table 1).

8 Diastolic dysfunction was detected using echocardiography in 470 (72.0%) of the subjects.  
9 These subjects were older and had a higher BMI, higher blood pressure, higher blood glucose,  
10 higher triglycerides, and lower HDL-C levels. However, the NT-proBNP level did not differ  
11 significantly between subjects with and without diastolic dysfunction (Table 2). Although  
12 subjects with both structural abnormality and diastolic dysfunction were older, higher LVMI,  
13 higher E/e' compared to one of structural abnormality or diastolic dysfunction, NT-proBNP  
14 was higher in those with structural abnormality only (data not shown).

15 In a multivariate model, being older, being female, and having a lower BMI, higher  
16 creatinine level, higher LVMI, and higher LAD were associated with an increased NT-proBNP  
17 level ( $P < 0.01$ ). While sex was not associated with the NT-proBNP level in a univariate model,  
18 being female was associated with increased NT-proBNP level ( $P = 0.002$ ) in multivariate model  
19 (Table 3). Among subjects in all age ranges (aged  $\leq 45$ , 46–60 years, and aged  $\geq 61$  years),  
20 females showed higher NT-proBNP levels than males (Figure 1). A structural abnormality  
21 defined by higher LVMI and/or higher LAD was associated with an increased NT-proBNP  
22 level ( $P < 0.01$ ) but the E/e' ratio and mean e' velocity were not associated with NT-proBNP. In  
23 subjects aged 46–60, and  $\geq 61$  years, those with structural abnormality showed a higher NT-



1  
2  
3  
4 1 proBNP level ( $P=0.002$  and  $P=0.004$ , respectively) (Figure 2).  
5  
6

7 2 Figure 3 shows the receiver operating curve for assessing the performance of NT-proBNP  
8  
9 3 in predicting cardiac structural abnormalities. AUROC was 0.625 (95% CI: 0.566–0.684). The  
10  
11 4 cutoff for NT-proBNP at 21.0 pg/mL had sensitivity of 51.1% (95% CI: 40.9%–61.3%),  
12  
13 5 specificity of 69.3% (95% CI: 65.5%–73.1%), positive predictive value of 21.5% (95% CI:  
14  
15 6 16.0–26.9%) and negative predictive value (NPV) of 89.6% (95% CI: 86.7%–92.5%) in  
16  
17 7 predicting cardiac structural abnormalities.  
18  
19  
20  
21  
22 8  
23  
24  
25 9  
26  
27  
28 10  
29  
30  
31 11  
32  
33  
34 12  
35  
36 13  
37  
38  
39 14  
40  
41  
42 15  
43  
44  
45 16  
46  
47  
48 17  
49  
50  
51 18  
52  
53  
54 19  
55  
56  
57 20  
58  
59  
60

## 1 **DISCUSSION**

2 This study investigated the association between NT-proBNP levels with echocardiography-  
3 detected early stage of cardiac structural abnormalities and diastolic dysfunction in  
4 asymptomatic subjects with preserved left ventricular systolic function in a primary healthcare  
5 setting. Subjects with structural abnormalities that were not yet apparent, were older and had a  
6 higher BMI, higher blood pressure, lower HDL-C level, or greater impairment of diastolic  
7 function in echocardiography. Furthermore, we have demonstrated that NT-proBNP levels are  
8 associated with preclinical cardiac structural abnormalities but not with diastolic dysfunction.

9 We observed associations of diastolic dysfunction with cardiovascular risk factors such as  
10 higher BMI, blood pressure, blood glucose, and triglycerides, and lower HDL-C levels. These  
11 results are consistent with reports of the presence of diastolic dysfunction being closely  
12 associated with cardiovascular diseases [16–18]. Furthermore, subjects with diastolic  
13 dysfunction exhibited elevated LVMI and LAD, which indicate the presence of structural  
14 abnormalities. These findings support that a hypertrophied ventricle is more likely to exhibit  
15 diastolic dysfunction and a chronic increase in the left atrial pressure associated with diastolic  
16 dysfunction, and would be expected to lead to atrial enlargement [19].

17 NT-proBNP is released into the circulation in response to a stretched myocardium resulting  
18 from any cardiac structural abnormalities [20]. Hung et al. [21] demonstrated an association  
19 between any structural anomaly and NT-proBNP levels, which was consistent with our finding  
20 of the NT-proBNP level being associated with subclinical cardiac structural abnormalities. Our  
21 AUROC suggest a threshold level of 21.0 pg/mL to exclude early stage of subclinical structural  
22 abnormalities in health checkups. Compared to previously recommended cutoff value of 32.8  
23 pg/mL [21], our newly proposed cutoff value is much lower with fairly acceptable NPV.

1  
2  
3  
4 1 However, we found no association between preclinical diastolic dysfunction (PDD) and the  
5  
6 2 circulating NT-proBNP level. These differences might be due to differences between the  
7  
8 3 included subjects: our study subjects participated in routine health checkups and pre-excluded  
9  
10 4 any echocardiography-detected valvular heart disease or pulmonary hypertension, while the  
11  
12 5 subjects included in the previous study had aortic root dilatation, ventricular hypertrophy,  
13  
14 6 pulmonary hypertension or valvular heart disease and presented at a tertiary referral center.  
15  
16 7 Another previous study of PDD [22] found that while advanced diastolic dysfunction with a  
17  
18 8 normal LVEF was independently associated with structural abnormalities (increased LVMI  
19  
20 9 and left atrial volume index [LAVI]) and increased circulating NT-proBNP, the structural  
21  
22 10 abnormalities and NT-proBNP levels did not differ between normal controls and patients with  
23  
24 11 mild diastolic dysfunction.  
25  
26  
27  
28  
29

30 12 Among subjects with a normal LVEF and no HF diagnosis, a higher severity of diastolic  
31  
32 13 dysfunction was associated with a higher mean LVMI and LAVI [19]. Our subjects with  
33  
34 14 diastolic dysfunction had relatively low mean LVMI or LAD values, and they are therefore  
35  
36 15 likely to have had only mild diastolic dysfunction. Our observations suggest that the association  
37  
38 16 between PDD and circulating NT-proBNP levels may vary according to the severity of diastolic  
39  
40 17 dysfunction. Therefore, the screening of preclinical structural or functional abnormalities based  
41  
42 18 on NT-proBNP levels could be optimized by targeting subjects with potentially advanced  
43  
44 19 diastolic dysfunction, which encompasses those who are older and have cardiovascular risk  
45  
46 20 factors such as obesity, hypertension, higher blood glucose or dyslipidemia in health checkups.  
47  
48  
49

50  
51 21 Our study has some limitations. Its cross-sectional design and relatively small sample mean  
52  
53 22 that further research is needed into the associated causal relationships. Nevertheless, power  
54  
55 23 calculation using G\* power 3.1 with effect size  $f^2$  of 0.2 (recommended by Cohen) showed the  
56  
57  
58  
59  
60

1  
2  
3  
4 1 efficiency of sample size as the power of 0.85, which seems to be available in drawing  
5  
6 2 conclusions of this study. Data on potential clinical correlates of diastolic dysfunction such  
7  
8 3 as exercise tolerance were not included. Moreover, the echocardiographic evaluation was  
9  
10 4 performed using a minimal data set that did not include detailed echocardiographic data on  
11  
12 5 diastolic function.  
13  
14  
15

16 6 In conclusion, the findings of this study suggest that NT-proBNP levels are associated with  
17  
18 7 preclinical cardiac structural abnormalities but not with diastolic dysfunction, which is  
19  
20 8 applicable to very early stage-B HF from among the four categories defined by the American  
21  
22 9 College of Cardiology/American Heart Association [23].  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 13 **Figure 1.** N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels according to sex and  
34 14 age categories. Box limits and horizontal lines within boxes represent interquartile ranges and  
35 15 the median, respectively. The upper and lower whiskers indicate the 97.5th and 2.5th  
36 16 percentiles, respectively.  
37  
38  
39

40 18 **Figure 2.** N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels of subjects with and  
41 19 without structural abnormalities according to age categories. Box limits and horizontal lines  
42 20 within boxes represent interquartile ranges and the median, respectively. The upper and lower  
43 21 whiskers indicate the 97.5th and 2.5th percentiles, respectively.  
44  
45  
46

47 23 Figure 3. Receiver operating characteristic curve and cutoff value of N-terminal pro-B-type  
48 24 natriuretic peptide (NT-proBNP) in predicting cardiac structural abnormalities.  
49  
50  
51

52 26 **Acknowledgements** The authors would like to thank the participants who made this study  
53  
54 27 possible.  
55  
56

57 28 **Author Contributions** All of the authors participated in designing this study. SC and SYK  
58  
59  
60

1 performed data collection. SK undertook the statistical analyses. EN, SYK, HC and SK  
2 analysed and interpreted the data. EN wrote the first draft of the manuscript, which was  
3 reviewed by all of the other authors, who also provided further contributions and suggestions.

4 **Funding** This research received no specific grant from any funding agency in the public or  
5 commercial sectors.

6 **Competing interests** None to declare.

7 **Patient consent** Obtained.

8 **Ethics approval** This study was approved by the Institutional Review Board of the Korea  
9 Association of Health Promotion (approval no. 130750-201807-HR-016).

10 **Provenance and peer review** Not commissioned; externally peer reviewed.

11 **Data sharing statement** No additional data are available.

12 **Open access**

## 1 REFERENCES

1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2016;37:2129–200.
2. Felker GM, Anstrom KJ, Adams KF, et al. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. *JAMA* 2017;318:713–20.
3. Davies M, Hobbs F, Davis R, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. *Lancet* 2001;358:439–44.
4. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. *Eur Heart J* 1999;20:447–55.
5. Mureddu GF, Agabiti N, Rizzello V, et al. Prevalence of preclinical and clinical heart failure in the elderly. A population-based study in Central Italy. *Eur J Heart Fail* 2012;14:718–29.
6. Fischer M, Baessler A, Hense HW, et al. Prevalence of left ventricular diastolic dysfunction in the community: Results from a Doppler echocardiographic-based survey of a population sample. *Eur Heart J* 2003;24:320–8.
7. Kuznetsova T, Herbots L, López B, et al. Prevalence of left ventricular diastolic dysfunction in a general population. *Circ Heart Fail* 2009;2:105–12.
8. Yu J, Oh PC, Kim M, et al. Improved early risk stratification of patients with ST-segment

- 1  
2  
3  
4 1 elevation myocardial infarction undergoing primary percutaneous coronary intervention  
5  
6 2 using a combination of serum soluble ST2 and NT-proBNP. *PLoS One* 2017;12:e0182829.  
7  
8  
9 3 9. Hall C. Essential biochemistry and physiology of (NT-pro) BNP. *Eur J Heart Fail*  
10  
11 4 2004;6:257–60.  
12  
13 5 10. Coats CJ, Parisi V, Ramos M, et al. Role of serum N-terminal pro-brain natriuretic peptide  
14  
15 6 measurement in diagnosis of cardiac involvement in patients with Anderson-Fabry disease.  
16  
17 7 *Am J Cardiol* 2013;111:111–7.  
18  
19 8 11. Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart failure: a  
20  
21 9 consensus statement on the diagnosis of heart failure with normal left ventricular ejection  
22  
23 10 fraction by the Heart Failure and Echocardiography Associations of the European Society  
24  
25 11 of Cardiology. *Eur Heart J* 2007;28:2539–50.  
26  
27 12 12. Gehle P, Robinson PN, Heinzl F, et al. NT-proBNP and diastolic left ventricular function  
28  
29 13 in patients with Marfan syndrome. *Int J Cardiol Heart Vasc* 2016;12:15–20.  
30  
31 14 13. Folland ED, Parisi AF, Moynihan PF, et al. Assessment of left ventricular ejection fraction  
32  
33 15 and volumes by real-time, two-dimensional echocardiography. A comparison of  
34  
35 16 cineangiographic and radionuclide techniques. *Circulation* 1979;60:760-6.  
36  
37 17 14. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber  
38  
39 18 quantification by echocardiography in adults: an update from the American Society of  
40  
41 19 Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J*  
42  
43 20 *Cardiovasc Imaging* 2015;16:233–71.  
44  
45 21 15. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left  
46  
47 22 ventricular diastolic function by echocardiography: an update from the American Society  
48  
49 23 of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc*  
50  
51 24 *Echocardiogr* 2016;29:277–314.  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 1 16. Kane GC, Karon BL, Mahoney DW, et al. Progression of left ventricular diastolic  
5  
6 2 dysfunction and risk of heart failure. *JAMA* 2011;306:856–63.  
7  
8  
9 3 17. From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes  
10  
11 4 mellitus and pre-clinical diastolic dysfunction: a population-based study. *J Am Coll Cardiol*  
12  
13 5 2010;55:300–5.  
14  
15 6 18. Ren X, Ristow B, Na B, et al. Prevalence and prognosis of asymptomatic left ventricular  
16  
17 7 diastolic dysfunction in ambulatory patients with coronary heart disease. *Am J Cardiol*  
18  
19 8 2007;99:1643–7.  
20  
21  
22 9 19 Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and diastolic ventricular  
23  
24 10 dysfunction in the community: appreciating the scope of the heart failure epidemic. *JAMA*  
25  
26 11 2003;289:194–202.  
27  
28  
29 12 20. Mueller T, Gegenhuber A, Poelz W, et al. Comparison of the Biomedica NT-proBNP  
30  
31 13 enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay:  
32  
33 14 implications for the prediction of symptomatic and asymptomatic structural heart disease.  
34  
35 15 *Clin Chem* 2003;49:976–9.  
36  
37  
38 16 21. Hung TC, Wang KT, Yun CH, et al. Value of serum N-terminal B-type natriuretic peptide  
39  
40 17 in asymptomatic structural heart disease in Taiwanese population: Comparisons with  
41  
42 18 current ESC Guidelines. *Int J Cardiol* 2017;231:195–200.  
43  
44  
45 19 22. Abhayaratna WP, Marwick TH, Smith WT, et al. Characteristics of left ventricular diastolic  
46  
47 20 dysfunction in the community: an echocardiographic survey. *Heart* 2006;92:1259–64.  
48  
49  
50 21 23. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management  
51  
52 22 of heart failure: a report of the American College of Cardiology Foundation/American  
53  
54 23 Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2013;62:e147–  
55  
56 24 239.  
57  
58  
59  
60



1

2

3

Table 1 Characteristics of study subjects according to the presence of structural abnormalities

Variables	No Structural abnormality	Structural abnormality	P Value
	(N=560)	(N=92)	
Age (year)	57.7 ± 8.9	60.8 ± 8.8	0.017
Gender Male, N (%)	309 (55.2)	52 (56.5)	0.432
BMI (kg/m <sup>2</sup> )	24.2 ± 3.0	26.9 ± 3.5	<0.001
SBP (mmHg)	119.8 ± 13.7	126.6 ± 12.1	<0.001
DBP (mmHg)	73.7 ± 8.9	76.9 ± 8.6	0.003
Hb (g/L)	147.7 ± 14.6	146.3 ± 16.5	0.965
FBS (mmol/L)	5.9 ± 1.5	6.2 ± 1.5	0.289
TC (mmol/L)	5.4 ± 1.1	5.2 ± 1.0	0.110
TG (mmol/L)	1.4 ± 0.9	1.6 ± 1.1	0.125
HDL-C (mmol/L)	1.5 ± 0.4	1.4 ± 0.4	<0.001
LDL-C (mmol/L)	3.2 ± 1	3.1 ± 0.9	0.236
Creatinine (µmol/L)	78.5 ± 15.2	76.9 ± 15.7	0.520
eGFR (mL/min/1.73m <sup>2</sup> )	85.3 ± 14.7	87.3 ± 18.4	0.639
NT-proBNP (pg/mL)	29.6 ± 27.5	55.8 ± 91.5	0.015
LVEF (%)	66 ± 6.5	64.9 ± 7.3	0.807
LVMI (g/m <sup>2</sup> )	71.7 ± 13.3	88.9 ± 18.1	<0.001
LAD (mL/m <sup>2</sup> )	33.7 ± 3.9	40.8 ± 5.5	<0.001
E/e'	11 ± 3.4	13 ± 3.5	0.002
e' (cm/s)	6.2 ± 1.6	5.9 ± 5.4	0.950

4 Continuous variables are expressed as mean±SD values and were compared using Student's *t*-test.

5 Categorical variables are expressed as N (%) values and were analyzed using the chi-square test.

6 NT-proBNP, N-terminal pro-B-type natriuretic peptide; BMI, body mass index; SBP, systolic blood  
7 pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglyceride; HDL-C, HDL-

1 cholesterol; LDL-C, LDL-cholesterol; FBS, fasting blood sugar; LVEF, left ventricular ejection fraction;  
 2 LVMI, left ventricular mass index; LAD, left atrial dimension; E/e', early diastolic mitral inflow  
 3 velocity/early diastolic mitral annular velocity; e', mean e' septal and lateral wall velocity.  
 4

5 Table 2. Characteristics of study subjects according to the presence of diastolic dysfunction

Variables	No diastolic dysfunction	Diastolic dysfunction	P Value
	(N=182)	(N=470)	
Age (year)	52.6 ± 8.8	60.3 ± 8.1	<0.001
Gender Male, N (%)	93 (51.1)	268 (57.0)	0.172
BMI (kg/m <sup>2</sup> )	23.4 ± 3	25 ± 3.2	<0.001
SBP (mmHg)	116.2 ± 12.6	122.6 ± 13.7	<0.001
DBP (mmHg)	71.4 ± 8.6	75.3 ± 8.8	<0.001
Hb (g/L)	144 ± 15.2	148.9 ± 14.5	<0.001
FBS (mmol/L)	5.6 ± 1	6.1 ± 1.6	<0.001
TC (mmol/L)	5.4 ± 1	5.4 ± 1.1	0.958
TG (mmol/L)	1.2 ± 0.8	1.5 ± 1	<0.001
HDL-C (mmol/L)	1.6 ± 0.4	1.5 ± 0.4	<0.001
LDL-C (mmol/L)	3.2 ± 1	3.2 ± 1	0.996
Creatinine (µmol/L)	76.3 ± 15.5	79 ± 15.2	0.040
eGFR (mL/min/1.73m <sup>2</sup> )	88.9 ± 15.7	84.3 ± 15	0.001
NT-proBNP (pg/mL)	35.9 ± 63.5	32.3 ± 32.9	0.476
LVEF (%)	65.2 ± 6.9	66.1 ± 6.5	0.131
LVMI (g/m <sup>2</sup> )	69.5 ± 14.2	75.9 ± 15.3	<0.001
LAD (mL/m <sup>2</sup> )	33.9 ± 5.1	35 ± 4.7	0.007
E/e'	9.4 ± 2.1	12 ± 3.6	<0.001
e' (cm/s)	8.4 ± 3.6	5.3 ± 1	<0.001

6 Continuous variables are expressed as mean±SD values and were compared using Student's *t*-test.  
 7 Categorical variables are expressed as N (%) values and were analyzed using the chi-square test.  
 8 NT-proBNP, N-terminal pro-B-type natriuretic peptide; BMI, body mass index; SBP, systolic blood  
 9 pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglyceride; HDL-C, HDL-

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 cholesterol; LDL-C, LDL-cholesterol; FBS, fasting blood sugar; LVEF, left ventricular ejection fraction;  
2 LVMI, left ventricular mass index; LAD, left atrial dimension; E/e', early diastolic mitral inflow  
3 velocity/early diastolic mitral annular velocity; e', mean e' septal and lateral wall velocity.

For peer review only

1 Table 3. Regression analysis of the variables affecting an increased NT-proBNP level

Variables	Univariate model				Multivariate model							
	Coeff.	95% CI	P-value	R <sup>2</sup>	Model 1				Model 2			
	Coeff.	95% CI	P-value	R <sup>2</sup>	Coeff.*	95% CI	P-value	R <sup>2</sup>	Coeff.	95% CI	P-value	R <sup>2</sup>
Age (year)	0.97	(0.6–1.33)	<0.001	0.040	0.58	(0.15– 1.01)	0.008	0.153	0.51	(0.13– 0.89)	0.009	0.140
Sex (ref: female)	-0.52	(-7.27– 6.23)	0.879	<0.001	-17.31	(-28.12– -6.51)	0.002		-19.47	(-28.5– -10.45)	<0.001	
BMI (kg/m <sup>2</sup> )	-0.26	(-1.3– 0.78)	0.626	<0.001	-1.97	(-3.2 –0.74)	0.002		-2.34	(-3.47– -1.21)	<0.001	
SBP (mmHg)	0.14	(-0.1–0.39)	0.258	0.002	-0.25	(-0.61– 0.1)	0.165					
DBP (mmHg)	0.27	(-0.11– 0.64)	0.164	0.003	0.48	(-0.06– 1.01)	0.081					
Hb (g/L)	-0.14	(-0.37– 0.08)	0.216	0.002	-0.15	(-0.45– 0.15)	0.338					
FBS (mmol/L)	-0.97	(-3.22– 1.28)	0.396	0.001	-0.44	(-2.71– 1.84)	0.707					
TG (mmol/L)	-2.34	(-5.81– 1.13)	0.186	0.003	-2.01	(-5.8– 1.78)	0.298					
HDL-C (mmol/L)	-1.72	(-10.2– 6.77)	0.691	<0.001	-0.76	(-9.82– 8.31)	0.870					
LDL-C (mmol/L)	-3.62	(-6.96– -0.27)	0.034	0.007	-2.95	(-6.2– 0.3)	0.075					
Creatinine (µmol/L)	0.36	(0.14– 0.58)	0.001	0.016	0.70	(0.4– 0.99)	<0.001		0.68	(0.4 –0.97)	<0.001	
LVEF (%)	-0.01	(-0.51– 0.49)	0.968	<0.001	0.12	(-0.37– 0.6)	0.637					
LVMI (g/m <sup>2</sup> )	0.47	(0.26– 0.69)	<0.001	0.028	0.28	(0.04– 0.52)	0.022		0.30	(0.07– 0.53)	0.012	
LAD (mL/m <sup>2</sup> )	2.11	(1.43– 2.79)	<0.001	0.054	2.58	(1.79– 3.37)	<0.001		2.63	(1.85– 3.41)	<0.001	
E/e'	0.65	(-0.33– 1.63)	0.191	0.003	-0.14	(-1.24– 0.97)	0.806					
e' (cm/s)	-0.54	(-1.87– 0.8)	0.430	0.001	0.38	(-1.04– 1.81)	0.597					


\*Regression coefficient: the usual interpretation of a regression coefficient is the average change in the outcome variable when the corresponding predictor variable is changed by one unit.

Model 1: adjust for age, sex, BMI, blood pressure, Hb, FBS, blood lipid creatinine

Model 2: adjusted for age, sex, BMI, creatinine, LVMI, and LAD


NT-proBNP, N-terminal pro-B-type natriuretic peptide; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglyceride; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; FBS, fasting blood sugar; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; LAD, left atrial dimension; E/e', early diastolic mitral inflow velocity/early diastolic mitral annular velocity; e', mean e' septal and lateral wall velocit.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels according to sex and age categories. Box limits and horizontal lines within boxes represent interquartile ranges and the median, respectively. The upper and lower whiskers indicate the 97.5th and 2.5th percentiles, respectively.

256x180mm (96 x 96 DPI)



N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels of subjects with and without structural abnormalities according to age categories. Box limits and horizontal lines within boxes represent interquartile ranges and the median, respectively. The upper and lower whiskers indicate the 97.5th and 2.5th percentiles, respectively.

256x171mm (96 x 96 DPI)



Receiver operating characteristic curve and cutoff value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in predicting cardiac structural abnormalities.

241x233mm (96 x 96 DPI)

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Title
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	3
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	4
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5,6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5,6
Bias	9	Describe any efforts to address potential sources of bias	Not relevant
Study size	10	Explain how the study size was arrived at	10
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5,6
		(b) Describe any methods used to examine subgroups and interactions	5,6
		(c) Explain how missing data were addressed	Not relevant
		(d) If applicable, describe analytical methods taking account of sampling strategy	Not relevant
		(e) Describe any sensitivity analyses	No
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Not relevant
		(b) Give reasons for non-participation at each stage	Not relevant
		(c) Consider use of a flow diagram	Not relevant
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	Not relevant
Outcome data	15*	Report numbers of outcome events or summary measures	7,8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make	Not relevant



		clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	Not relevant
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not relevant
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Not relevant
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	9-11
Generalisability	21	Discuss the generalisability (external validity) of the study results	9
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

**Plasma NT-proBNP levels are associated with cardiac structural abnormalities, but not with diastolic dysfunction, in asymptomatic health promotion centre attendees with preserved ejection fraction: a retrospective cross-sectional study**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026030.R2
Article Type:	Research
Date Submitted by the Author:	20-Feb-2019
Complete List of Authors:	Nah, Eun-Hee; Korea Association of Health Promotion, Health promotion research institute Kim, Seong Yoon ; Korea Association of Health Promotion, Division of Cardiology, Department of Internal Medicine Cho, Seon; Korea Association of Health Promotion, Health promotion research institute Kim, Suyoung; Korea Association of Health Promotion, Health promotion research institute Cho, Han-Ik ; Korea Association of Health Promotion, MEDiCheck LAB
<b>Primary Subject Heading</b>:	Cardiovascular medicine
Secondary Subject Heading:	Diagnostics
Keywords:	Heart failure < CARDIOLOGY, NT-proBNP, Echocardiography < CARDIOLOGY, Preclinical structural abnormalities, Diastolic dysfunction

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 1 **Title page**

5  
6  
7 2 **Plasma NT-proBNP levels are associated with cardiac structural**  
8 **abnormalities, but not with diastolic dysfunction, in asymptomatic health**  
9 **promotion centre attendees with preserved ejection fraction: a retrospective**  
10 **cross-sectional study**  
11  
12  
13  
14  
15  
16

17  
18 7 Eun-Hee Nah,<sup>1</sup> Seong Yoon Kim,<sup>2</sup> Seon Cho,<sup>1</sup> Suyoung Kim,<sup>1</sup> Han-Ik Cho,<sup>3</sup>

19  
20 8 <sup>1</sup>Department of Laboratory Medicine and Health Promotion Research Institute, Korea  
21 Association of Health Promotion, Seoul, Korea; <sup>2</sup>Division of Cardiology, Department of  
22 Internal Medicine, Korea Association of Health Promotion, Seoul, Korea; <sup>3</sup>MEDiCheck LAB,  
23 Korea Association of Health Promotion, Cheongju, Korea  
24  
25  
26  
27  
28  
29

30 13 Corresponding author: Eun-Hee Nah

31  
32 14 Department of Laboratory Medicine and Health Promotion Research Institute, Korea  
33 Association of Health Promotion,  
34  
35 16 350 Hwagokro, Kangseo-Gu, Seoul 07653, Korea

36  
37 17 Tel.: +82-2-2600-0107

38  
39 18 Fax: +82-2-2690-4915

40  
41 19 E-mail: [cellonah@hanmail.net](mailto:cellonah@hanmail.net), [cellonah@kahp.or.kr](mailto:cellonah@kahp.or.kr)  
42  
43  
44  
45  
46  
47  
48  
49  
50

51 22 **Keywords:** Heart failure, NT-proBNP, Echocardiography, Preclinical structural abnormalities,  
52  
53 23 Diastolic dysfunction

54  
55  
56 24 **Word counts:** 2,061  
57  
58  
59  
60

## 1 ABSTRACT

2 **Objectives:** Stage B heart failure is defined as an asymptomatic abnormality of the heart  
3 structure or function. The circulating level of N-terminal pro-B-type natriuretic peptide (NT-  
4 proBNP) is elevated in symptomatic patients with left ventricular (LV) dysfunction caused by  
5 a structural or functional abnormality. This study investigated the association of the NT-  
6 proBNP level with echocardiography detected cardiac structural or diastolic abnormalities in  
7 asymptomatic subjects with preserved LV systolic function (ejection fraction >50%).

8 **Methods:** We retrospectively studied 652 health examinees who underwent echocardiography  
9 and NT-proBNP test at a health-promotion center in Seoul, between January 2016 and  
10 September 2018. The left ventricular mass index (LVMI), and left atrial dimension (LAD) were  
11 used as markers for structural abnormalities, and the mean e' velocity and E/e' ratio were used  
12 as markers for diastolic dysfunction. The plasma NT-proBNP level was measured using  
13 electrochemiluminescence immunoassay (DPC Immulite 2000 XPi, Siemens Healthcare  
14 Diagnostics, Tarrytown, NY, USA).

15 **Results:** Subjects with preclinical structural abnormalities were older and had a higher body  
16 mass index (BMI), higher blood pressure, lower high-density lipoprotein cholesterol level,  
17 higher NT-proBNP level, and higher E/e' ( $P<0.05$ ). Multivariate regression analysis indicated  
18 that the factors associated with a higher NT-proBNP level were older age, female sex, and  
19 lower BMI, higher creatinine level, higher LVMI and higher LAD ( $P<0.01$ ).

20 **Conclusion:** Diastolic dysfunction is not associated with higher NT-proBNP levels, whereas,  
21 preclinical cardiac structural abnormalities as well as older age, female sex, lower BMI, and  
22 higher creatinine level are associated with higher NT-proBNP levels.

### 1 **Strengths and limitations of this study**

- 2 ■ This is the first study to address the association of early stage of preclinical  
3 echocardiography-detected cardiac structural or diastolic abnormalities with the NT-  
4 proBNP level in a primary healthcare setting.
- 5 ■ The target subjects with potential cardiac structural abnormalities for screening early  
6 stage B heart failure would be selected based on the NT-proBNP levels in health  
7 checkups.
- 8 ■ The cross-sectional study design and the relatively small sample mean that further  
9 research is needed into the associated causal relationships.

## 1 INTRODUCTION

2 Heart failure (HF) is a clinical syndrome characterized by typical symptoms and signs caused  
3 by a structural and/or functional cardiac abnormalities that result in a reduced pumping  
4 capability of heart and its pre- and post-loading volumes, stasis of blood flow, and insufficiency  
5 of the blood and oxygen supplied to the main organs [1]. The incidence of cardiovascular  
6 diseases is increasing including in younger subjects due to changes in lifestyles and dietary  
7 patterns, and there have also been increases in the rates of progression to HF [2]. Systolic  
8 dysfunction is frequently present in community-dwelling individuals without recognized  
9 symptoms of HF [3, 4]. In addition, most subjects with diastolic dysfunction have a normal left  
10 ventricular ejection fraction (LVEF), with even moderate or severe isolated diastolic  
11 dysfunction being as common as systolic dysfunction [5–7]. Thus, the early recognition and  
12 treatment of preclinical structural or functional abnormalities represent a potentially powerful  
13 strategy for reducing the incidence of HF.

14 N-terminal pro-B-type natriuretic peptide (NT-proBNP) is produced within myocytes and  
15 released into the circulation during increases in the ventricular and atrial pressures [8, 9]. The  
16 NT-proBNP level is therefore a useful diagnostic marker for cardiac insufficiency [10],  
17 ventricular dysfunction [11] and cardiomyopathy [12]. An assay for measuring the NT-proBNP  
18 level may also be applied for detecting asymptomatic subclinical cardiac structural or  
19 functional impairment. However, few studies have investigated the association between NT-  
20 proBNP levels and the early stage of preclinical structural or functional heart abnormalities,  
21 which are checked by echocardiography performed as a part of preventive screening programs  
22 in the primary healthcare system.

23 This study investigated the association of the NT-proBNP level with echocardiography-

1  
2  
3  
4 1 detected early stage of cardiac structural or diastolic abnormalities in asymptomatic subjects  
5  
6 2 with preserved left ventricular systolic function (LVEF >50%) during health checkups.  
7  
8

### 9 3 **METHODS**

#### 10 4 **Subjects**

11  
12  
13  
14  
15 5 We retrospectively studied consecutive health examinees aged over 18-year old who underwent  
16  
17 6 echocardiography and NT-proBNP test during health checkups at a health-promotion center in  
18  
19 7 Seoul between January 2016 and September 2018. The study design was retrospective and  
20  
21 8 cross-sectional. The self-reported personal medical history, subjective symptoms and signs,  
22  
23 9 and life style information were obtained from all participants at time of health checkups. Their  
24  
25 10 medical records were also reviewed. Inclusion criteria were preserved left ventricular systolic  
26  
27 11 function (LVEF >50%) determined by echocardiography, no previous cardiac surgery or  
28  
29 12 diagnosed heart disease. Subjects who had echocardiography-detected valvular heart disease,  
30  
31 13 atrial fibrillation, acute myocardial infarction, stroke, renal dysfunction, pregnancy,  
32  
33 14 echocardiography-detected LVEF < 50%, or clinical symptoms or signs of HF were excluded  
34  
35 15 from this study. After exclusion, the final sample size was 652 (361 males and 291 females:  
36  
37 16 aged 28–82)  
38  
39  
40  
41  
42  
43

44 17 This study was approved by the Institutional Review Board of Korea Association of Health  
45  
46 18 Promotion (approval no. 130750-201807-HR-016).  
47  
48

#### 49 19 **Echocardiography**

50  
51  
52 20 The echocardiographic investigations were carried out using a Philips/Hewlett-Packard Sono  
53  
54 21 5500 ultrasound device (Philips Ultrasound, Andover, MA, USA). M-mode, two-dimensional,  
55  
56 22 and hemodynamic Doppler images were acquired using a standardized protocol with a 3.5-  
57  
58  
59  
60

1  
2  
3  
4 1 MHZ transducer. LVEF was calculated using the modified Simpson method [13]. An increased  
5  
6 2 left ventricular mass index (LVMI;  $>115$  g/m<sup>2</sup> in males and  $>95$  g/m<sup>2</sup> in females), and an  
7  
8 3 increased left atrial dimension (LAD;  $>41$  mm in males and  $>39$  mm in females) were used as  
9  
10 4 markers for structural abnormalities [14]. Cardiac diastolic dysfunction was defined as an early  
11  
12 5 diastolic mitral flow velocity (E)/early relaxation velocity in tissue Doppler recordings ( $e'$ )  $\geq 13$   
13  
14 6 and a mean  $e'$  septal and lateral wall  $<9$  cm/s. [15].  
15  
16  
17  
18

### 19 7 **NT-proBNP measurement**

20  
21 8 Venous blood was collected in an lithium-heparin tube. The plasma NT-proBNP level was  
22  
23 9 measured using an electrochemiluminescent immunoassay on a DPC Immulite 2000 XPi  
24  
25 10 device (Siemens Healthcare Diagnostics, Tarrytown, NY, USA). The intra-assay and total  
26  
27 11 variances were 3.4% and 4.7%, respectively, and the limit of detection was 10 pg/mL.  
28  
29  
30

### 31 12 **Statistical analysis**

32  
33  
34 13 Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA).  
35  
36 14 Differences in the characteristics of the study subjects were analyzed according to the presence  
37  
38 15 of structural abnormalities using Student's *t*-test or the chi-square test. In addition, differences  
39  
40 16 in the characteristics of the study subjects were analyzed according to the presence of diastolic  
41  
42 17 dysfunction using Student's *t*-test or the chi-square test. Differences in the characteristics of  
43  
44 18 those with structural abnormality, diastolic dysfunction, or both abnormalities were analyzed  
45  
46 19 using ANOVA. Univariate (crude) and multivariate (adjusted) regression analyses were  
47  
48 20 performed to determine the variables affecting an increased NT-proBNP level. Variables  
49  
50 21 considered in the analysis included age, sex, body mass index (BMI), systolic blood pressure,  
51  
52 22 diastolic blood pressure, hemoglobin (Hb), fasting blood glucose (FBS), triglyceride, HDL-  
53  
54 23 cholesterol, LDL-cholesterol, creatinine, LVEF, LVMI, LAD, E/ $e'$  and  $e'$ . We used multiple  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 1 linear regression model to control for effects of included age, sex, BMI, blood pressure, Hb, FBS,  
5  
6 2 blood lipid, creatinine, LVEF, LVMI, LAD, E/e' and e' (Model 1). Additional regression model  
7  
8 3 adjusted for age, sex, BMI, creatinine, LVMI, and LAD was used to identify increased NT-  
9  
10 4 proBNP level in multivariate model (Model 2). Wilcoxon rank sum tests were performed to  
11  
12 5 compare mean NT-proBNP levels between sexes, and between with and without structural  
13  
14 6 abnormalities in each age groups, respectively. In addition, Wilcoxon rank sum test was used  
15  
16 7 to compare those with diastolic dysfunction to those without diastolic dysfunction. Logarithmic  
17  
18 8 transformations were applied to NT-proBNP level. Area under the receiver operating curve  
19  
20 9 (AUROC) was calculated to measure the performance of NT-proBNP in predicting the cardiac  
21  
22 10 structural abnormalities. A *P* value of <0.05 was considered statistically significant.  
23  
24  
25  
26  
27

### 28 11 **Patient and public involvement**

29  
30  
31 12 Patients were not involved in the recruitment to and conduct of the study. Results will be  
32  
33 13 disseminated to study participants through annual information events.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 RESULTS

2 Six hundred and fifty-two of the 876 eligible subjects were analyzed (Figure 1). The median  
3 age of the study subjects was 58 years (range 28–82 years). Echocardiography revealed  
4 structural abnormalities in 92 (14.1%) of the subjects, who were older ( $60.8\pm 8.8$  vs  $57.7\pm 8.9$   
5 years [mean $\pm$ SD],  $P<0.017$ ), and had a higher BMI, higher blood pressure, lower high-density  
6 lipoprotein cholesterol (HDL-C) level, higher NT-proBNP level ( $55.8\pm 91.5$  vs  $29.6\pm 27.5$   
7 pg/mL,  $P=0.015$ ), and higher E/e' ratio ( $13.0\pm 3.5$  vs  $11.0\pm 3.4$ ) in echocardiography (Table 1).

8 Diastolic dysfunction was detected using echocardiography in 470 (72.0%) of the subjects.  
9 These subjects were older and had a higher BMI, higher blood pressure, higher FBS, higher  
10 triglycerides, and lower HDL-C levels. However, the NT-proBNP level did not differ  
11 significantly between subjects with and without diastolic dysfunction (Table 2). Although  
12 subjects with both structural abnormality and diastolic dysfunction were older, higher blood  
13 pressure, higher FBS, higher triglyceride, higher LVMI, higher E/e', and lower e' compared to  
14 one of structural abnormality or diastolic dysfunction, NT-proBNP was higher in subjects with  
15 structural abnormality only (Table 3).

16 In a univariate model, older age, lower LDL-C level, higher creatinine level, higher LVMI,  
17 and higher LAD were associated with an increased NT-proBNP level. In a multivariate model,  
18 older age, female sex, lower BMI, higher creatinine level, higher LVMI, and higher LAD were  
19 associated with an increased NT-proBNP level ( $P<0.01$ ). While sex was not associated with  
20 the NT-proBNP level in a univariate model, female sex was associated with increased NT-  
21 proBNP level ( $P=0.002$ ) in multivariate model (Table 4). Among subjects in all age ranges  
22 (aged  $\leq 45$ , 46–60 years, and aged  $\geq 61$  years), females showed higher NT-proBNP levels than  
23 males (Figure 2). A structural abnormality defined by higher LVMI and/or higher LAD was

1  
2  
3  
4 1 associated with an increased NT-proBNP level ( $P<0.01$ ) but the E/e' ratio and mean e' velocity  
5  
6 2 were not associated with NT-proBNP level. In subjects aged 46–60, and  $\geq 61$  years, those with  
7  
8 3 structural abnormality showed a higher NT-proBNP level ( $P=0.002$  and  $P=0.004$ , respectively)  
9  
10  
11 4 (Figure 3).  
12  
13

14 5 Figure 4 shows the receiver operating curve for assessing the performance of NT-proBNP  
15  
16 6 in predicting cardiac structural abnormalities. AUROC was 0.625 (95% CI: 0.566–0.684). The  
17  
18 7 cutoff for NT-proBNP at 21.0 pg/mL had sensitivity of 51.1% (95% CI: 40.9%–61.3%),  
19  
20 8 specificity of 69.3% (95% CI: 65.5%–73.1%), positive predictive value of 21.5% (95% CI:  
21  
22 9 16.0–26.9%) and negative predictive value (NPV) of 89.6% (95% CI: 86.7%–92.5%) in  
23  
24 10 predicting cardiac structural abnormalities.  
25  
26  
27  
28  
29 11  
30  
31  
32 12  
33  
34 13  
35  
36  
37 14  
38  
39  
40 15  
41  
42  
43 16  
44  
45  
46 17  
47  
48  
49 18  
50  
51  
52 19  
53  
54  
55 20  
56  
57  
58  
59  
60

## 1 DISCUSSION

2 This study investigated the association between NT-proBNP levels with echocardiography-  
3 detected early stage of cardiac structural abnormalities and diastolic dysfunction in  
4 asymptomatic subjects with preserved left ventricular systolic function in a primary healthcare  
5 setting. Subjects with structural abnormalities that were not yet apparent, were older and had a  
6 higher BMI, higher blood pressure, lower HDL-C level, or greater impairment of diastolic  
7 function in echocardiography. Furthermore, we have demonstrated that diastolic dysfunction  
8 is not associated with higher NT-proBNP levels, whereas, preclinical cardiac structural  
9 abnormalities as well as older age, female sex, lower BMI, and higher creatinine level are  
10 associated with higher NT-proBNP levels.

11 We observed associations of diastolic dysfunction with cardiovascular risk factors such as  
12 higher BMI, blood pressure, FBS, and triglycerides, and lower HDL-C levels. These results are  
13 consistent with reports of the presence of diastolic dysfunction being closely associated with  
14 cardiovascular diseases [16–18]. Furthermore, subjects with diastolic dysfunction exhibited  
15 elevated LVMI and LAD, which indicate the presence of structural abnormalities. These  
16 findings support that a hypertrophied ventricle is more likely to exhibit diastolic dysfunction  
17 and a chronic increase in the left atrial pressure associated with diastolic dysfunction, and  
18 would be expected to lead to atrial enlargement [19].

19 NT-proBNP is released into the circulation in response to a stretched myocardium resulting  
20 from any cardiac structural abnormalities [20]. Hung et al. [21] demonstrated an association  
21 between any structural anomaly and NT-proBNP levels, which was consistent with our finding  
22 of the NT-proBNP level being associated with subclinical cardiac structural abnormalities. Our  
23 AUROC suggest a threshold level of 21.0 pg/mL to exclude early stage of subclinical structural

1  
2  
3  
4 1 abnormalities in health checkups. Compared to previously recommended cutoff value of 32.8  
5  
6 2 pg/mL [21], our newly proposed cutoff value is much lower with fairly acceptable NPV.  
7  
8  
9 3 However, we found no association between preclinical diastolic dysfunction (PDD) and the  
10  
11 4 circulating NT-proBNP level. These differences might be due to differences between the  
12  
13 5 included subjects: our study subjects participated in routine health checkups and pre-excluded  
14  
15 6 any echocardiography-detected valvular heart disease or pulmonary hypertension, while the  
16  
17 7 subjects included in the previous study had aortic root dilatation, ventricular hypertrophy,  
18  
19 8 pulmonary hypertension or valvular heart disease and presented at a tertiary referral center.  
20  
21 9 Another previous study of PDD [22] found that while advanced diastolic dysfunction with a  
22  
23 10 normal LVEF was independently associated with structural abnormalities (increased LVMI  
24  
25 11 and left atrial volume index [LAVI]) and increased circulating NT-proBNP, the structural  
26  
27 12 abnormalities and NT-proBNP levels did not differ between normal controls and patients with  
28  
29 13 mild diastolic dysfunction.

30  
31  
32  
33  
34  
35 14 Among subjects with a normal LVEF and no HF diagnosis, a higher severity of diastolic  
36  
37 15 dysfunction was associated with a higher mean LVMI and LAVI [19]. Our subjects with  
38  
39 16 diastolic dysfunction had relatively low mean LVMI or LAD values, and they are therefore  
40  
41 17 likely to have had only mild diastolic dysfunction. Our observations suggest that the association  
42  
43 18 between PDD and circulating NT-proBNP levels may vary according to the severity of diastolic  
44  
45 19 dysfunction. Therefore, the screening of preclinical structural or functional abnormalities based  
46  
47 20 on NT-proBNP levels could be optimized by targeting subjects with potentially advanced  
48  
49 21 diastolic dysfunction, which encompasses those who are older and have cardiovascular risk  
50  
51 22 factors such as obesity, hypertension, higher blood glucose or dyslipidemia in health checkups.

52  
53  
54  
55  
56 23 Our study has some limitations. Its cross-sectional design and relatively small sample mean  
57  
58  
59  
60

1 that further research is needed into the associated causal relationships. Nevertheless, power  
2 calculation using G\* power 3.1 with effect size  $f^2$  of 0.2 (recommended by Cohen) showed the  
3 efficiency of sample size as the power of 0.85, which seems to be available in drawing  
4 conclusions of this study. Data on potential clinical correlates of diastolic dysfunction such as  
5 exercise tolerance were not included. Moreover, the echocardiographic evaluation was  
6 performed using a minimal data set that did not include detailed echocardiographic data on  
7 diastolic function. American Society of Echocardiography 2016 guidelines recommended the  
8 four variables for identifying diastolic dysfunction: annular  $e'$  velocity, average  $E/e'$  ratio, LA  
9 maximum volume index, and peak TR velocity. And the average  $E/e'$  ratio, which was used in  
10 the present study, was recommended for simplification on the basis of the writing group's  
11 collective expert opinion [15]. Inclusion of other variables will be considered to differentiate  
12 between normal and abnormal diastolic function in the future study.

13 In conclusion, the findings of this study suggest that NT-proBNP levels are associated with  
14 preclinical cardiac structural but not with diastolic dysfunction, which is applicable to early  
15 stage-B HF among the four categories defined by the American College of  
16 Cardiology/American Heart Association [23].

18 **Figure 1.** Study flow diagram.

20 **Figure 2.** N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels according to sex and  
21 age categories. Box limits and horizontal lines within boxes represent interquartile ranges and  
22 the median, respectively. The upper and lower whiskers indicate the 97.5th and 2.5th  
23 percentiles, respectively.

25 **Figure 3.** N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels of subjects with and  
26 without structural abnormalities according to age categories. Box limits and horizontal lines

1  
2  
3  
4 1 within boxes represent interquartile ranges and the median, respectively. The upper and lower  
5 2 whiskers indicate the 97.5th and 2.5th percentiles, respectively.  
6  
7 3  
8

9 4 **Figure 4.** Receiver operating characteristic curve and cutoff value of N-terminal pro-B-type  
10 5 natriuretic peptide (NT-proBNP) in predicting cardiac structural abnormalities.  
11  
12 6  
13

14 7 **Acknowledgements** The authors would like to thank the participants who made this study  
15  
16 8 possible.  
17  
18

19 9 **Author Contributions** All of the authors participated in designing this study. SC and SYK  
20 10 performed data collection. SK undertook the statistical analyses. EN, SYK, HC and SK  
21 11 analysed and interpreted the data. EN wrote the first draft of the manuscript, which was  
22 12 reviewed by all of the other authors, who also provided further contributions and suggestions.  
23  
24  
25  
26  
27  
28

29 13 **Funding** This research received no specific grant from any funding agency in the public or  
30 14 commercial sectors.  
31  
32  
33

34 15 **Competing interests** None to declare.  
35  
36

37 16 **Patient consent** Obtained.  
38  
39

40 17 **Ethics approval** This study was approved by the Institutional Review Board of the Korea  
41 18 Association of Health Promotion (approval no. 130750-201807-HR-016).  
42  
43  
44

45 19 **Provenance and peer review** Not commissioned; externally peer reviewed.  
46  
47

48 20 **Data sharing statement** No additional data are available.  
49  
50

51 21 **Open access**  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 REFERENCES

1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2016;37:2129–200.
2. Felker GM, Anstrom KJ, Adams KF, et al. Effect of natriuretic peptide–guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. *JAMA* 2017;318:713–20.
3. Davies M, Hobbs F, Davis R, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. *Lancet* 2001;358:439–44.
4. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. *Eur Heart J* 1999;20:447–55.
5. Mureddu GF, Agabiti N, Rizzello V, et al. Prevalence of preclinical and clinical heart failure in the elderly. A population-based study in Central Italy. *Eur J Heart Fail* 2012;14:718–29.
6. Fischer M, Baessler A, Hense HW, et al. Prevalence of left ventricular diastolic dysfunction in the community: Results from a Doppler echocardiographic-based survey of a population sample. *Eur Heart J* 2003;24:320–8.
7. Kuznetsova T, Herbots L, López B, et al. Prevalence of left ventricular diastolic dysfunction in a general population. *Circ Heart Fail* 2009;2:105–12.
8. Yu J, Oh PC, Kim M, et al. Improved early risk stratification of patients with ST-segment



- 1  
2  
3  
4 1 elevation myocardial infarction undergoing primary percutaneous coronary intervention  
5  
6 2 using a combination of serum soluble ST2 and NT-proBNP. *PLoS One* 2017;12:e0182829.  
7  
8  
9 3 9. Hall C. Essential biochemistry and physiology of (NT-pro) BNP. *Eur J Heart Fail*  
10  
11 4 2004;6:257–60.  
12  
13 5 10. Coats CJ, Parisi V, Ramos M, et al. Role of serum N-terminal pro-brain natriuretic peptide  
14  
15 6 measurement in diagnosis of cardiac involvement in patients with Anderson-Fabry disease.  
16  
17 7 *Am J Cardiol* 2013;111:111–7.  
18  
19 8 11. Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart failure: a  
20  
21 9 consensus statement on the diagnosis of heart failure with normal left ventricular ejection  
22  
23 10 fraction by the Heart Failure and Echocardiography Associations of the European Society  
24  
25 11 of Cardiology. *Eur Heart J* 2007;28:2539–50.  
26  
27 12 12. Gehle P, Robinson PN, Heinzl F, et al. NT-proBNP and diastolic left ventricular function  
28  
29 13 in patients with Marfan syndrome. *Int J Cardiol Heart Vasc* 2016;12:15–20.  
30  
31 14 13. Folland ED, Parisi AF, Moynihan PF, et al. Assessment of left ventricular ejection fraction  
32  
33 15 and volumes by real-time, two-dimensional echocardiography. A comparison of  
34  
35 16 cineangiographic and radionuclide techniques. *Circulation* 1979;60:760-6.  
36  
37 17 14. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber  
38  
39 18 quantification by echocardiography in adults: an update from the American Society of  
40  
41 19 Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J*  
42  
43 20 *Cardiovasc Imaging* 2015;16:233–71.  
44  
45 21 15. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left  
46  
47 22 ventricular diastolic function by echocardiography: an update from the American Society  
48  
49 23 of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc*  
50  
51 24 *Echocardiogr* 2016;29:277–314.  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 1 16. Kane GC, Karon BL, Mahoney DW, et al. Progression of left ventricular diastolic  
5  
6 2 dysfunction and risk of heart failure. *JAMA* 2011;306:856–63.  
7  
8  
9 3 17. From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes  
10  
11 4 mellitus and pre-clinical diastolic dysfunction: a population-based study. *J Am Coll Cardiol*  
12  
13 5 2010;55:300–5.  
14  
15  
16 6 18. Ren X, Ristow B, Na B, et al. Prevalence and prognosis of asymptomatic left ventricular  
17  
18 7 diastolic dysfunction in ambulatory patients with coronary heart disease. *Am J Cardiol*  
19  
20 8 2007;99:1643–7.  
21  
22  
23 9 19 Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and diastolic ventricular  
24  
25 10 dysfunction in the community: appreciating the scope of the heart failure epidemic. *JAMA*  
26  
27 11 2003;289:194–202.  
28  
29  
30 12 20. Mueller T, Gegenhuber A, Poelz W, et al. Comparison of the Biomedica NT-proBNP  
31  
32 13 enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay:  
33  
34 14 implications for the prediction of symptomatic and asymptomatic structural heart disease.  
35  
36 15 *Clin Chem* 2003;49:976–9.  
37  
38  
39 16 21. Hung TC, Wang KT, Yun CH, et al. Value of serum N-terminal B-type natriuretic peptide  
40  
41 17 in asymptomatic structural heart disease in Taiwanese population: Comparisons with  
42  
43 18 current ESC Guidelines. *Int J Cardiol* 2017;231:195–200.  
44  
45  
46 19 22. Abhayaratna WP, Marwick TH, Smith WT, et al. Characteristics of left ventricular diastolic  
47  
48 20 dysfunction in the community: an echocardiographic survey. *Heart* 2006;92:1259–64.  
49  
50  
51 21 23. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management  
52  
53 22 of heart failure: a report of the American College of Cardiology Foundation/American  
54  
55 23 Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2013;62:e147–  
56  
57 24 239.  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

3 Table 1 Characteristics of study subjects according to the presence of structural abnormalities

Variables	No Structural abnormality	Structural abnormality	P Value
	(N=560)	(N=92)	
Age (year)	57.7 ± 8.9	60.8 ± 8.8	0.017
Gender Male, N (%)	309 (55.2)	52 (56.5)	0.432
BMI (kg/m <sup>2</sup> )	24.2 ± 3.0	26.9 ± 3.5	<0.001
SBP (mmHg)	119.8 ± 13.7	126.6 ± 12.1	<0.001
DBP (mmHg)	73.7 ± 8.9	76.9 ± 8.6	0.003
Hb (g/L)	147.7 ± 14.6	146.3 ± 16.5	0.965
FBS (mmol/L)	5.9 ± 1.5	6.2 ± 1.5	0.289
TC (mmol/L)	5.4 ± 1.1	5.2 ± 1.0	0.110
TG (mmol/L)	1.4 ± 0.9	1.6 ± 1.1	0.125
HDL-C (mmol/L)	1.5 ± 0.4	1.4 ± 0.4	<0.001
LDL-C (mmol/L)	3.2 ± 1	3.1 ± 0.9	0.236
Creatinine (µmol/L)	78.5 ± 15.2	76.9 ± 15.7	0.520
eGFR (mL/min/1.73m <sup>2</sup> )	85.3 ± 14.7	87.3 ± 18.4	0.639
NT-proBNP (pg/mL)	29.6 ± 27.5	55.8 ± 91.5	0.015
LVEF (%)	66 ± 6.5	64.9 ± 7.3	0.807
LVMI (g/m <sup>2</sup> )	71.7 ± 13.3	88.9 ± 18.1	<0.001
LAD (mL/m <sup>2</sup> )	33.7 ± 3.9	40.8 ± 5.5	<0.001
E/e'	11 ± 3.4	13 ± 3.5	0.002
e' (cm/s)	6.2 ± 1.6	5.9 ± 5.4	0.950

4 Continuous variables are expressed as mean±SD values and were compared using Student's *t*-test.  
5 Categorical variables are expressed as N (%) values and were analyzed using the chi-square test.  
6 NT-proBNP, N-terminal pro-B-type natriuretic peptide; BMI, body mass index; SBP, systolic blood  
7 pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglyceride; HDL-C, HDL-

1 cholesterol; LDL-C, LDL-cholesterol; FBS, fasting blood sugar; LVEF, left ventricular ejection fraction;  
 2 LVMI, left ventricular mass index; LAD, left atrial dimension; E/e', early diastolic mitral inflow  
 3 velocity/early diastolic mitral annular velocity; e', mean e' septal and lateral wall velocity.  
 4

5 Table 2 Characteristics of study subjects according to the presence of diastolic dysfunction

Variables	No diastolic dysfunction	Diastolic dysfunction	P Value
	(N=182)	(N=470)	
Age (year)	52.6 ± 8.8	60.3 ± 8.1	<0.001
Gender Male, N (%)	93 (51.1)	268 (57.0)	0.172
BMI (kg/m <sup>2</sup> )	23.4 ± 3	25 ± 3.2	<0.001
SBP (mmHg)	116.2 ± 12.6	122.6 ± 13.7	<0.001
DBP (mmHg)	71.4 ± 8.6	75.3 ± 8.8	<0.001
Hb (g/L)	144 ± 15.2	148.9 ± 14.5	<0.001
FBS (mmol/L)	5.6 ± 1	6.1 ± 1.6	<0.001
TC (mmol/L)	5.4 ± 1	5.4 ± 1.1	0.958
TG (mmol/L)	1.2 ± 0.8	1.5 ± 1	<0.001
HDL-C (mmol/L)	1.6 ± 0.4	1.5 ± 0.4	<0.001
LDL-C (mmol/L)	3.2 ± 1	3.2 ± 1	0.996
Creatinine (µmol/L)	76.3 ± 15.5	79 ± 15.2	0.040
eGFR (mL/min/1.73m <sup>2</sup> )	88.9 ± 15.7	84.3 ± 15	0.001
NT-proBNP (pg/mL)	35.9 ± 63.5	32.3 ± 32.9	0.476
LVEF (%)	65.2 ± 6.9	66.1 ± 6.5	0.131
LVMI (g/m <sup>2</sup> )	69.5 ± 14.2	75.9 ± 15.3	<0.001
LAD (mL/m <sup>2</sup> )	33.9 ± 5.1	35 ± 4.7	0.007
E/e'	9.4 ± 2.1	12 ± 3.6	<0.001
e' (cm/s)	8.4 ± 3.6	5.3 ± 1	<0.001

6 Continuous variables are expressed as mean±SD values and were compared using Student's *t*-test.  
 7 Categorical variables are expressed as N (%) values and were analyzed using the chi-square test.  
 8 NT-proBNP, N-terminal pro-B-type natriuretic peptide; BMI, body mass index; SBP, systolic blood  
 9 pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglyceride; HDL-C, HDL-

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 cholesterol; LDL-C, LDL-cholesterol; FBS, fasting blood sugar; LVEF, left ventricular ejection fraction;  
2 LVMI, left ventricular mass index; LAD, left atrial dimension; E/e', early diastolic mitral inflow  
3 velocity/early diastolic mitral annular velocity; e', mean e' septal and lateral wall velocity.

For peer review only

1 Table 3 Characteristics of study subjects according to the presence of structural abnormalities and/or diastolic dysfunction

Variables	Normal <sup>a</sup>		Structural abnormality <sup>b</sup>		Diastolic dysfunction <sup>c</sup>		Structural abnormality & Diastolic dysfunction <sup>d</sup>		P-Value	Multiple comparison
	(N=167)		(N=15)		(N=393)		(N=77)			
Age (year)	52.5	± 8.8	54.8	± 8.9	59.9	± 8	62	± 8.3	<0.001	a,b < c,d
Gender Male, N (%)	82	(49.1)	11	(73.3)	227	(57.8)	41	(53.3)	0.129	-
BMI (kg/m <sup>2</sup> )	23.2	± 3	25.9	± 2.1	24.6	± 2.9	27.1	± 3.7	<0.001	a < d
SBP (mmHg)	115.7	± 12.6	121.3	± 11.5	121.6	± 13.8	127.6	± 12	<0.001	a < d
DBP (mmHg)	71.2	± 8.7	73	± 8	74.8	± 8.8	77.6	± 8.5	<0.001	a,b < d
Hb (g/L)	143.7	± 15.1	147.3	± 16.6	149.4	± 14.1	146.1	± 16.6	<0.001	-
FBS (mmol/L)	5.6	± 1	5.5	± 1	6.1	± 1.6	6.4	± 1.5	<0.001	b < d
TC (mmol/L)	5.4	± 1	5.1	± 1.3	5.4	± 1.1	5.3	± 0.9	0.631	-
TG (mmol/L)	1.2	± 0.8	0.9	± 0.7	1.4	± 1	1.7	± 1.1	<0.001	b < d
HDL-C (mmol/L)	1.6	± 0.4	1.5	± 0.5	1.5	± 0.4	1.4	± 0.4	0.001	a > d
LDL-C (mmol/L)	3.2	± 1	3.2	± 1	3.3	± 1	3.1	± 0.9	0.618	-
Creatinine (µmol/L)	75.4	± 15.1	85.5	± 18.2	79.7	± 15.2	75.2	± 14.7	0.001	a,d < b
eGFR (mL/min/1.73m <sup>2</sup> )†	89.5	± 15.8	82.3	± 13.1	83.5	± 13.9	88.3	± 19.2	<0.001	b < a
NT-proBNP (pg/mL)†	27.1	± 16	132.9	± 195.2	30.7	± 31.1	40.8	± 40	0.005	a,c,d < b
LVEF (%)†	65.3	± 6.3	63.8	± 12	66.3	± 6.6	65.2	± 6.2	0.272	-
LVMI (g/m <sup>2</sup> )†	67.8	± 12.8	88	± 16.2	73.3	± 13.1	89.1	± 18.5	<0.001	a,c < b,d
LAD (mL/m <sup>2</sup> )†	33	± 3.9	43.5	± 6.2	34	± 3.8	40.2	± 5.2	<0.001	a,c < d < b
E/e'†	9.3	± 2.1	10.7	± 2.4	11.8	± 3.5	13.4	± 3.5	<0.001	a < b,c < d
e' (cm/s)†	8.2	± 1.1	11	± 12.3	5.4	± 0.9	4.9	± 1.2	<0.001	d,c < a < b

2 †Welch's ANOVA (not equal variance) was used.

3 NT-proBNP, N-terminal pro-B-type natriuretic peptide; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total  
4 cholesterol; TG, triglyceride; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; FBS, fasting blood sugar; LVEF, left ventricular ejection fraction;  
5 LVMI, left ventricular mass index; LAD, left atrial dimension; E/e', early diastolic mitral inflow velocity/early diastolic mitral annular velocity; e', mean  
6 e' septal and lateral wall velocity.

1 Table 4 Regression analysis of the variables affecting an increased NT-proBNP level

Variables	Univariate model				Multivariate model							
					Model 1				Model 2			
	Coeff.*	95% CI	P-value	R <sup>2</sup>	Coeff.*	95% CI	P-value	R <sup>2</sup>	Coeff.*	95% CI	P-value	R <sup>2</sup>
Age (year)	0.97	(0.6–1.33)	<0.001	0.040	0.58	(0.15– 1.01)	0.008	0.153	0.51	(0.13– 0.89)	0.009	0.140
Sex (ref: female)	-0.52	(-7.27– 6.23)	0.879	<0.001	-17.31	(-28.12– -6.51)	0.002		-19.47	(-28.5– -10.45)	<0.001	
BMI (kg/m <sup>2</sup> )	-0.26	(-1.3– 0.78)	0.626	<0.001	-1.97	(-3.2 – -0.74)	0.002		-2.34	(-3.47– -1.21)	<0.001	
SBP (mmHg)	0.14	(-0.1–0.39)	0.258	0.002	-0.25	(-0.61– 0.1)	0.165					
DBP (mmHg)	0.27	(-0.11– 0.64)	0.164	0.003	0.48	(-0.06– 1.01)	0.081					
Hb (g/L)	-0.14	(-0.37– 0.08)	0.216	0.002	-0.15	(-0.45– 0.15)	0.338					
FBS (mmol/L)	-0.97	(-3.22– 1.28)	0.396	0.001	-0.44	(-2.71– 1.84)	0.707					
TG (mmol/L)	-2.34	(-5.81– 1.13)	0.186	0.003	-2.01	(-5.8– 1.78)	0.298					
HDL-C (mmol/L)	-1.72	(-10.2– 6.77)	0.691	<0.001	-0.76	(-9.82– 8.31)	0.870					
LDL-C (mmol/L)	-3.62	(-6.96– -0.27)	0.034	0.007	-2.95	(-6.2– 0.3)	0.075					
Creatinine (µmol/L)	0.36	(0.14– 0.58)	0.001	0.016	0.70	(0.4– 0.99)	<0.001		0.68	(0.4 –0.97)	<0.001	
LVEF (%)	-0.01	(-0.51– 0.49)	0.968	<0.001	0.12	(-0.37– 0.6)	0.637					
LVMI (g/m <sup>2</sup> )	0.47	(0.26– 0.69)	<0.001	0.028	0.28	(0.04– 0.52)	0.022		0.30	(0.07– 0.53)	0.012	
LAD (mL/m <sup>2</sup> )	2.11	(1.43– 2.79)	<0.001	0.054	2.58	(1.79– 3.37)	<0.001		2.63	(1.85– 3.41)	<0.001	
E/e'	0.65	(-0.33– 1.63)	0.191	0.003	-0.14	(-1.24– 0.97)	0.806					
e' (cm/s)	-0.54	(-1.87– 0.8)	0.430	0.001	0.38	(-1.04– 1.81)	0.597					

2 \*Regression coefficient: the usual interpretation of a regression coefficient is the average change in the outcome variable when the corresponding predictor  
3 variable is changed by one unit.

4 Model 1: adjust for age, sex, BMI, blood pressure, Hb, FBS, blood lipid creatinine

5 Model 2: adjusted for age, sex, BMI, creatinine, LVMI, and LAD

6 NT-proBNP, N-terminal pro-B-type natriuretic peptide; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total  
7 cholesterol; TG, triglyceride; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; FBS, fasting blood sugar; LVEF, left ventricular ejection fraction; LVMI,  
8 left ventricular mass index; LAD, left atrial dimension; E/e', early diastolic mitral inflow velocity/early diastolic mitral annular velocity; e', mean e' septal  
9 and lateral wall velocity.




Figure 1 Study flow diagram.

Figure 1 Study flow diagram.

208x116mm (96 x 96 DPI)






Figure 2 N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels according to sex and age categories. Box limits and horizontal lines within boxes represent interquartile ranges and the median, respectively. The upper and lower whiskers indicate the 97.5th and 2.5th percentiles, respectively.

Figure 2 N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels according to sex and age categories. Box limits and horizontal lines within boxes represent interquartile ranges and the median, respectively. The upper and lower whiskers indicate the 97.5th and 2.5th percentiles, respectively.

163x131mm (96 x 96 DPI)





Figure 3 N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels of subjects with and without structural abnormalities according to age categories. Box limits and horizontal lines within boxes represent interquartile ranges and the median, respectively. The upper and lower whiskers indicate the 97.5th and 2.5th percentiles, respectively.

Figure 3 N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels of subjects with and without structural abnormalities according to age categories. Box limits and horizontal lines within boxes represent interquartile ranges and the median, respectively. The upper and lower whiskers indicate the 97.5th and 2.5th percentiles, respectively.

161x124mm (96 x 96 DPI)



**Figure 4** Receiver operating characteristic curve and cutoff value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in predicting cardiac structural abnormalities.

Figure 4 Receiver operating characteristic curve and cutoff value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in predicting cardiac structural abnormalities.

162x115mm (96 x 96 DPI)

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Title
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	3
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	4
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5,6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5,6
Bias	9	Describe any efforts to address potential sources of bias	Not relevant
Study size	10	Explain how the study size was arrived at	10
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5,6
		(b) Describe any methods used to examine subgroups and interactions	5,6
	(c) Explain how missing data were addressed	Not relevant	
	(d) If applicable, describe analytical methods taking account of sampling strategy	Not relevant	
	(e) Describe any sensitivity analyses	No	
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Not relevant
		(b) Give reasons for non-participation at each stage	Not relevant
		(c) Consider use of a flow diagram	Not relevant
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	Not relevant
Outcome data	15*	Report numbers of outcome events or summary measures	7,8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make	Not relevant

		clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	Not relevant
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not relevant
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Not relevant
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	9-11
Generalisability	21	Discuss the generalisability (external validity) of the study results	9
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Plasma NT-proBNP levels associated with cardiac structural abnormalities in asymptomatic health examinees with preserved ejection fraction: a retrospective cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026030.R3
Article Type:	Research
Date Submitted by the Author:	25-Feb-2019
Complete List of Authors:	Nah, Eun-Hee; Korea Association of Health Promotion, Helath promotion research institute Kim, Seong Yoon ; Korea Association of Health Promotion, Division of Cardiology, Department of Internal Medicine Cho, Seon; Korea Association of Health Promotion, Helath promotion research institute Kim, Suyoung; Korea Association of Health Promotion, Helath promotion research institute Cho, Han-Ik ; Korea Association of Health Promotion, MEDiCheck LAB
<b>Primary Subject Heading</b>:	Cardiovascular medicine
Secondary Subject Heading:	Diagnostics
Keywords:	Heart failure < CARDIOLOGY, NT-proBNP, Echocardiography < CARDIOLOGY, Preclinical structural abnormalities, Diastolic dysfunction

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 1 **Title page**

5  
6  
7 2 **Plasma NT-proBNP levels associated with cardiac structural abnormalities**  
8 **in asymptomatic health examinees with preserved ejection fraction: a**  
9 **retrospective cross-sectional study**  
10  
11  
12  
13  
14  
15

16 6 Eun-Hee Nah,<sup>1</sup> Seong Yoon Kim,<sup>2</sup> Seon Cho,<sup>1</sup> Suyoung Kim,<sup>1</sup> Han-Ik Cho,<sup>3</sup>

17  
18 7 <sup>1</sup>Department of Laboratory Medicine and Health Promotion Research Institute, Korea  
19 8 Association of Health Promotion, Seoul, Korea; <sup>2</sup>Division of Cardiology, Department of  
20 9 Internal Medicine, Korea Association of Health Promotion, Seoul, Korea; <sup>3</sup>MEDiCheck LAB,  
21 10 Korea Association of Health Promotion, Cheongju, Korea  
22  
23  
24  
25

26 11  
27  
28 12 Corresponding author: Eun-Hee Nah

29  
30  
31 13 Department of Laboratory Medicine and Health Promotion Research Institute, Korea  
32 14 Association of Health Promotion,  
33  
34 15 350 Hwagokro, Kangseo-Gu, Seoul 07653, Korea

35  
36  
37 16 Tel.: +82-2-2600-0107

38  
39 17 Fax: +82-2-2690-4915

40  
41  
42 18 E-mail: [cellonah@hanmail.net](mailto:cellonah@hanmail.net), [cellonah@kahp.or.kr](mailto:cellonah@kahp.or.kr)  
43  
44  
45  
46

47 20 **Keywords:** Heart failure, NT-proBNP, Echocardiography, Preclinical structural abnormalities,  
48  
49 21 Diastolic dysfunction  
50  
51

52  
53  
54  
55 23 **Word counts:** 2,061  
56  
57  
58  
59  
60

## 1 ABSTRACT

2 **Objectives:** Stage B heart failure is defined as an asymptomatic abnormality of the heart  
3 structure or function. The circulating level of N-terminal pro-B-type natriuretic peptide (NT-  
4 proBNP) is elevated in symptomatic patients with left ventricular (LV) dysfunction caused by  
5 a structural or functional abnormality. This study investigated the association of the NT-  
6 proBNP level with echocardiography detected cardiac structural or diastolic abnormalities in  
7 asymptomatic subjects with preserved LV systolic function (ejection fraction >50%).

8 **Methods:** We retrospectively studied 652 health examinees who underwent echocardiography  
9 and NT-proBNP test at a health-promotion center in Seoul, between January 2016 and  
10 September 2018. The left ventricular mass index (LVMI), and left atrial dimension (LAD) were  
11 used as markers for structural abnormalities, and the mean e' velocity and E/e' ratio were used  
12 as markers for diastolic dysfunction. The plasma NT-proBNP level was measured using  
13 electrochemiluminescence immunoassay (DPC Immulite 2000 XPi, Siemens Healthcare  
14 Diagnostics, Tarrytown, NY, USA).

15 **Results:** Subjects with preclinical structural abnormalities were older and had a higher body  
16 mass index (BMI), higher blood pressure, lower high-density lipoprotein cholesterol level,  
17 higher NT-proBNP level, and higher E/e' ( $P<0.05$ ). Multivariate regression analysis indicated  
18 that the factors associated with a higher NT-proBNP level were older age, female sex, and  
19 lower BMI, higher creatinine level, higher LVMI and higher LAD ( $P<0.01$ ).

20 **Conclusion:** Diastolic dysfunction is not associated with higher NT-proBNP levels, whereas,  
21 preclinical cardiac structural abnormalities as well as older age, female sex, lower BMI, and  
22 higher creatinine level are associated with higher NT-proBNP levels.



### 1 **Strengths and limitations of this study**

- 2 ■ This is the first study to address the association of early stage of preclinical  
3 echocardiography-detected cardiac structural or diastolic abnormalities with the NT-  
4 proBNP level in a primary healthcare setting.
- 5 ■ The target subjects with potential cardiac structural abnormalities for screening early  
6 stage B heart failure would be selected based on the NT-proBNP levels in health  
7 checkups.
- 8 ■ The cross-sectional study design and the relatively small sample mean that further  
9 research is needed into the associated causal relationships.

## 1 INTRODUCTION

2 Heart failure (HF) is a clinical syndrome characterized by typical symptoms and signs caused  
3 by a structural and/or functional cardiac abnormalities that result in a reduced pumping  
4 capability of heart and its pre- and post-loading volumes, stasis of blood flow, and insufficiency  
5 of the blood and oxygen supplied to the main organs [1]. The incidence of cardiovascular  
6 diseases is increasing including in younger subjects due to changes in lifestyles and dietary  
7 patterns, and there have also been increases in the rates of progression to HF [2]. Systolic  
8 dysfunction is frequently present in community-dwelling individuals without recognized  
9 symptoms of HF [3, 4]. In addition, most subjects with diastolic dysfunction have a normal left  
10 ventricular ejection fraction (LVEF), with even moderate or severe isolated diastolic  
11 dysfunction being as common as systolic dysfunction [5–7]. Thus, the early recognition and  
12 treatment of preclinical structural or functional abnormalities represent a potentially powerful  
13 strategy for reducing the incidence of HF.

14 N-terminal pro-B-type natriuretic peptide (NT-proBNP) is produced within myocytes and  
15 released into the circulation during increases in the ventricular and atrial pressures [8, 9]. The  
16 NT-proBNP level is therefore a useful diagnostic marker for cardiac insufficiency [10],  
17 ventricular dysfunction [11] and cardiomyopathy [12]. An assay for measuring the NT-proBNP  
18 level may also be applied for detecting asymptomatic subclinical cardiac structural or  
19 functional impairment. However, few studies have investigated the association between NT-  
20 proBNP levels and the early stage of preclinical structural or functional heart abnormalities,  
21 which are checked by echocardiography performed as a part of preventive screening programs  
22 in the primary healthcare system.

23 This study investigated the association of the NT-proBNP level with echocardiography-

1  
2  
3  
4 1 detected early stage of cardiac structural or diastolic abnormalities in asymptomatic subjects  
5  
6 2 with preserved left ventricular systolic function (LVEF >50%) during health checkups.  
7  
8

### 9 3 **METHODS**

#### 10 4 **Subjects**

11  
12  
13  
14  
15 5 We retrospectively studied consecutive health examinees aged over 18-year old who underwent  
16  
17 6 echocardiography and NT-proBNP test during health checkups at a health-promotion center in  
18  
19 7 Seoul between January 2016 and September 2018. The study design was retrospective and  
20  
21 8 cross-sectional. The self-reported personal medical history, subjective symptoms and signs,  
22  
23 9 and life style information were obtained from all participants at time of health checkups. Their  
24  
25 10 medical records were also reviewed. Inclusion criteria were preserved left ventricular systolic  
26  
27 11 function (LVEF >50%) determined by echocardiography, no previous cardiac surgery or  
28  
29 12 diagnosed heart disease. Subjects who had echocardiography-detected valvular heart disease,  
30  
31 13 atrial fibrillation, acute myocardial infarction, stroke, renal dysfunction, pregnancy,  
32  
33 14 echocardiography-detected LVEF < 50%, or clinical symptoms or signs of HF were excluded  
34  
35 15 from this study. After exclusion, the final sample size was 652 (361 males and 291 females:  
36  
37 16 aged 28–82)

38  
39  
40  
41  
42  
43 17 This study was approved by the Institutional Review Board of Korea Association of Health  
44  
45 18 Promotion (approval no. 130750-201807-HR-016).

#### 46 47 48 49 19 **Echocardiography**

50  
51  
52 20 The echocardiographic investigations were carried out using a Philips/Hewlett-Packard Sono  
53  
54 21 5500 ultrasound device (Philips Ultrasound, Andover, MA, USA). M-mode, two-dimensional,  
55  
56 22 and hemodynamic Doppler images were acquired using a standardized protocol with a 3.5-

1  
2  
3  
4 1 MHZ transducer. LVEF was calculated using the modified Simpson method [13]. An increased  
5  
6 2 left ventricular mass index (LVMI;  $>115 \text{ g/m}^2$  in males and  $>95 \text{ g/m}^2$  in females), and an  
7  
8 3 increased left atrial dimension (LAD;  $>41 \text{ mm}$  in males and  $>39 \text{ mm}$  in females) were used as  
9  
10 4 markers for structural abnormalities [14]. Cardiac diastolic dysfunction was defined as an early  
11  
12 5 diastolic mitral flow velocity (E)/early relaxation velocity in tissue Doppler recordings ( $e'$ )  $\geq 13$   
13  
14 6 and a mean  $e'$  septal and lateral wall  $<9 \text{ cm/s}$ . [15].  
15  
16  
17  
18

### 19 7 **NT-proBNP measurement**

20  
21 8 Venous blood was collected in an lithium-heparin tube. The plasma NT-proBNP level was  
22  
23 9 measured using an electrochemiluminescent immunoassay on a DPC Immulite 2000 XPi  
24  
25 10 device (Siemens Healthcare Diagnostics, Tarrytown, NY, USA). The intra-assay and total  
26  
27 11 variances were 3.4% and 4.7%, respectively, and the limit of detection was 10 pg/mL.  
28  
29  
30

### 31 12 **Statistical analysis**

32  
33  
34 13 Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA).  
35  
36 14 Differences in the characteristics of the study subjects were analyzed according to the presence  
37  
38 15 of structural abnormalities using Student's *t*-test or the chi-square test. In addition, differences  
39  
40 16 in the characteristics of the study subjects were analyzed according to the presence of diastolic  
41  
42 17 dysfunction using Student's *t*-test or the chi-square test. Differences in the characteristics of  
43  
44 18 those with structural abnormality, diastolic dysfunction, or both abnormalities were analyzed  
45  
46 19 using ANOVA. Univariate (crude) and multivariate (adjusted) regression analyses were  
47  
48 20 performed to determine the variables affecting an increased NT-proBNP level. Variables  
49  
50 21 considered in the analysis included age, sex, body mass index (BMI), systolic blood pressure,  
51  
52 22 diastolic blood pressure, hemoglobin (Hb), fasting blood glucose (FBS), triglyceride, HDL-  
53  
54 23 cholesterol, LDL-cholesterol, creatinine, LVEF, LVMI, LAD, E/ $e'$  and  $e'$ . We used multiple  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 1 linear regression model to control for effects of included age, sex, BMI, blood pressure, Hb, FBS,  
5  
6 2 blood lipid, creatinine, LVEF, LVMI, LAD, E/e' and e' (Model 1). Additional regression model  
7  
8 3 adjusted for age, sex, BMI, creatinine, LVMI, and LAD was used to identify increased NT-  
9  
10 4 proBNP level in multivariate model (Model 2). Wilcoxon rank sum tests were performed to  
11  
12 5 compare mean NT-proBNP levels between sexes, and between with and without structural  
13  
14 6 abnormalities in each age groups, respectively. In addition, Wilcoxon rank sum test was used  
15  
16 7 to compare those with diastolic dysfunction to those without diastolic dysfunction. Logarithmic  
17  
18 8 transformations were applied to NT-proBNP level. Area under the receiver operating curve  
19  
20 9 (AUROC) was calculated to measure the performance of NT-proBNP in predicting the cardiac  
21  
22 10 structural abnormalities. A *P* value of <0.05 was considered statistically significant.  
23  
24  
25  
26  
27

### 28 11 **Patient and public involvement**

29  
30  
31 12 Patients were not involved in the recruitment to and conduct of the study. Results will be  
32  
33 13 disseminated to study participants through annual information events.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 RESULTS

2 Six hundred and fifty-two of the 876 eligible subjects were analyzed (Figure 1). The median  
3 age of the study subjects was 58 years (range 28–82 years). Echocardiography revealed  
4 structural abnormalities in 92 (14.1%) of the subjects, who were older ( $60.8\pm 8.8$  vs  $57.7\pm 8.9$   
5 years [mean $\pm$ SD],  $P<0.017$ ), and had a higher BMI, higher blood pressure, lower high-density  
6 lipoprotein cholesterol (HDL-C) level, higher NT-proBNP level ( $55.8\pm 91.5$  vs  $29.6\pm 27.5$   
7 pg/mL,  $P=0.015$ ), and higher E/e' ratio ( $13.0\pm 3.5$  vs  $11.0\pm 3.4$ ) in echocardiography (Table 1).

8 Diastolic dysfunction was detected using echocardiography in 470 (72.0%) of the subjects.  
9 These subjects were older and had a higher BMI, higher blood pressure, higher FBS, higher  
10 triglycerides, and lower HDL-C levels. However, the NT-proBNP level did not differ  
11 significantly between subjects with and without diastolic dysfunction (Table 2). Although  
12 subjects with both structural abnormality and diastolic dysfunction were older, higher blood  
13 pressure, higher FBS, higher triglyceride, higher LVMI, higher E/e', and lower e' compared to  
14 one of structural abnormality or diastolic dysfunction, NT-proBNP was higher in subjects with  
15 structural abnormality only (Table 3).

16 In a univariate model, older age, lower LDL-C level, higher creatinine level, higher LVMI,  
17 and higher LAD were associated with an increased NT-proBNP level. In a multivariate model,  
18 older age, female sex, lower BMI, higher creatinine level, higher LVMI, and higher LAD were  
19 associated with an increased NT-proBNP level ( $P<0.01$ ). While sex was not associated with  
20 the NT-proBNP level in a univariate model, female sex was associated with increased NT-  
21 proBNP level ( $P=0.002$ ) in multivariate model (Table 4). Among subjects in all age ranges  
22 (aged  $\leq 45$ , 46–60 years, and aged  $\geq 61$  years), females showed higher NT-proBNP levels than  
23 males (Figure 2). A structural abnormality defined by higher LVMI and/or higher LAD was

1  
2  
3  
4 1 associated with an increased NT-proBNP level ( $P<0.01$ ) but the E/e' ratio and mean e' velocity  
5  
6 2 were not associated with NT-proBNP level. In subjects aged 46–60, and  $\geq 61$  years, those with  
7  
8 3 structural abnormality showed a higher NT-proBNP level ( $P=0.002$  and  $P=0.004$ , respectively)  
9  
10  
11 4 (Figure 3).  
12  
13

14 5 Figure 4 shows the receiver operating curve for assessing the performance of NT-proBNP  
15  
16 6 in predicting cardiac structural abnormalities. AUROC was 0.625 (95% CI: 0.566–0.684). The  
17  
18 7 cutoff for NT-proBNP at 21.0 pg/mL had sensitivity of 51.1% (95% CI: 40.9%–61.3%),  
19  
20 8 specificity of 69.3% (95% CI: 65.5%–73.1%), positive predictive value of 21.5% (95% CI:  
21  
22 9 16.0–26.9%) and negative predictive value (NPV) of 89.6% (95% CI: 86.7%–92.5%) in  
23  
24 10 predicting cardiac structural abnormalities.  
25  
26  
27  
28  
29 11  
30  
31  
32 12  
33  
34 13  
35  
36  
37 14  
38  
39  
40 15  
41  
42  
43 16  
44  
45  
46 17  
47  
48  
49 18  
50  
51  
52 19  
53  
54  
55 20  
56  
57  
58  
59  
60

## 1 DISCUSSION

2 This study investigated the association between NT-proBNP levels with echocardiography-  
3 detected early stage of cardiac structural abnormalities and diastolic dysfunction in  
4 asymptomatic subjects with preserved left ventricular systolic function in a primary healthcare  
5 setting. Subjects with structural abnormalities that were not yet apparent, were older and had a  
6 higher BMI, higher blood pressure, lower HDL-C level, or greater impairment of diastolic  
7 function in echocardiography. Furthermore, we have demonstrated that diastolic dysfunction  
8 is not associated with higher NT-proBNP levels, whereas, preclinical cardiac structural  
9 abnormalities as well as older age, female sex, lower BMI, and higher creatinine level are  
10 associated with higher NT-proBNP levels.

11 We observed associations of diastolic dysfunction with cardiovascular risk factors such as  
12 higher BMI, blood pressure, FBS, and triglycerides, and lower HDL-C levels. These results are  
13 consistent with reports of the presence of diastolic dysfunction being closely associated with  
14 cardiovascular diseases [16–18]. Furthermore, subjects with diastolic dysfunction exhibited  
15 elevated LVMI and LAD, which indicate the presence of structural abnormalities. These  
16 findings support that a hypertrophied ventricle is more likely to exhibit diastolic dysfunction  
17 and a chronic increase in the left atrial pressure associated with diastolic dysfunction, and  
18 would be expected to lead to atrial enlargement [19].

19 NT-proBNP is released into the circulation in response to a stretched myocardium resulting  
20 from any cardiac structural abnormalities [20]. Hung et al. [21] demonstrated an association  
21 between any structural anomaly and NT-proBNP levels, which was consistent with our finding  
22 of the NT-proBNP level being associated with subclinical cardiac structural abnormalities. Our  
23 AUROC suggest a threshold level of 21.0 pg/mL to exclude early stage of subclinical structural



1  
2  
3  
4 1 abnormalities in health checkups. Compared to previously recommended cutoff value of 32.8  
5  
6 2 pg/mL [21], our newly proposed cutoff value is much lower with fairly acceptable NPV.  
7  
8  
9 3 However, we found no association between preclinical diastolic dysfunction (PDD) and the  
10  
11 4 circulating NT-proBNP level. These differences might be due to differences between the  
12  
13 5 included subjects: our study subjects participated in routine health checkups and pre-excluded  
14  
15 6 any echocardiography-detected valvular heart disease or pulmonary hypertension, while the  
16  
17 7 subjects included in the previous study had aortic root dilatation, ventricular hypertrophy,  
18  
19 8 pulmonary hypertension or valvular heart disease and presented at a tertiary referral center.  
20  
21 9 Another previous study of PDD [22] found that while advanced diastolic dysfunction with a  
22  
23 10 normal LVEF was independently associated with structural abnormalities (increased LVMI  
24  
25 11 and left atrial volume index [LAVI]) and increased circulating NT-proBNP, the structural  
26  
27 12 abnormalities and NT-proBNP levels did not differ between normal controls and patients with  
28  
29 13 mild diastolic dysfunction.

30  
31  
32  
33  
34  
35 14 Among subjects with a normal LVEF and no HF diagnosis, a higher severity of diastolic  
36  
37 15 dysfunction was associated with a higher mean LVMI and LAVI [19]. Our subjects with  
38  
39 16 diastolic dysfunction had relatively low mean LVMI or LAD values, and they are therefore  
40  
41 17 likely to have had only mild diastolic dysfunction. Our observations suggest that the association  
42  
43 18 between PDD and circulating NT-proBNP levels may vary according to the severity of diastolic  
44  
45 19 dysfunction. Therefore, the screening of preclinical structural or functional abnormalities based  
46  
47 20 on NT-proBNP levels could be optimized by targeting subjects with potentially advanced  
48  
49 21 diastolic dysfunction, which encompasses those who are older and have cardiovascular risk  
50  
51 22 factors such as obesity, hypertension, higher blood glucose or dyslipidemia in health checkups.

52  
53  
54  
55  
56 23 Our study has some limitations. Its cross-sectional design and relatively small sample mean  
57  
58  
59  
60

1 that further research is needed into the associated causal relationships. Nevertheless, power  
2 calculation using G\* power 3.1 with effect size  $f^2$  of 0.2 (recommended by Cohen) showed the  
3 efficiency of sample size as the power of 0.85, which seems to be available in drawing  
4 conclusions of this study. Data on potential clinical correlates of diastolic dysfunction such as  
5 exercise tolerance were not included. Moreover, the echocardiographic evaluation was  
6 performed using a minimal data set that did not include detailed echocardiographic data on  
7 diastolic function. American Society of Echocardiography 2016 guidelines recommended the  
8 four variables for identifying diastolic dysfunction: annular e' velocity, average E/e' ratio, LA  
9 maximum volume index, and peak TR velocity. And the average E/e' ratio, which was used in  
10 the present study, was recommended for simplification on the basis of the writing group's  
11 collective expert opinion [15]. Inclusion of other variables will be considered to differentiate  
12 between normal and abnormal diastolic function in the future study.

13 In conclusion, the findings of this study suggest that NT-proBNP levels are associated with  
14 preclinical cardiac structural but not with diastolic dysfunction, which is applicable to early  
15 stage-B HF among the four categories defined by the American College of  
16 Cardiology/American Heart Association [23].

18 **Figure 1.** Study flow diagram.

20 **Figure 2.** N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels according to sex and  
21 age categories. Box limits and horizontal lines within boxes represent interquartile ranges and  
22 the median, respectively. The upper and lower whiskers indicate the 97.5th and 2.5th  
23 percentiles, respectively.

25 **Figure 3.** N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels of subjects with and  
26 without structural abnormalities according to age categories. Box limits and horizontal lines

1  
2  
3  
4 1 within boxes represent interquartile ranges and the median, respectively. The upper and lower  
5 2 whiskers indicate the 97.5th and 2.5th percentiles, respectively.  
6  
7 3  
8

9 4 **Figure 4.** Receiver operating characteristic curve and cutoff value of N-terminal pro-B-type  
10 5 natriuretic peptide (NT-proBNP) in predicting cardiac structural abnormalities.  
11  
12 6  
13

14 7 **Acknowledgements** The authors would like to thank the participants who made this study  
15  
16 8 possible.  
17  
18

19 9 **Author Contributions** All of the authors participated in designing this study. SC and SYK  
20 10 performed data collection. SK undertook the statistical analyses. EN, SYK, HC and SK  
21 11 analysed and interpreted the data. EN wrote the first draft of the manuscript, which was  
22 12 reviewed by all of the other authors, who also provided further contributions and suggestions.  
23  
24  
25  
26  
27  
28

29 13 **Funding** This research received no specific grant from any funding agency in the public or  
30 14 commercial sectors.  
31  
32  
33

34 15 **Competing interests** None to declare.  
35  
36

37 16 **Patient consent** Obtained.  
38  
39

40 17 **Ethics approval** This study was approved by the Institutional Review Board of the Korea  
41 18 Association of Health Promotion (approval no. 130750-201807-HR-016).  
42  
43  
44

45 19 **Provenance and peer review** Not commissioned; externally peer reviewed.  
46  
47

48 20 **Data sharing statement** No additional data are available.  
49  
50

51 21 **Open access**  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 REFERENCES

1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2016;37:2129–200.
2. Felker GM, Anstrom KJ, Adams KF, et al. Effect of natriuretic peptide–guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. *JAMA* 2017;318:713–20.
3. Davies M, Hobbs F, Davis R, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. *Lancet* 2001;358:439–44.
4. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. *Eur Heart J* 1999;20:447–55.
5. Mureddu GF, Agabiti N, Rizzello V, et al. Prevalence of preclinical and clinical heart failure in the elderly. A population-based study in Central Italy. *Eur J Heart Fail* 2012;14:718–29.
6. Fischer M, Baessler A, Hense HW, et al. Prevalence of left ventricular diastolic dysfunction in the community: Results from a Doppler echocardiographic-based survey of a population sample. *Eur Heart J* 2003;24:320–8.
7. Kuznetsova T, Herbots L, López B, et al. Prevalence of left ventricular diastolic dysfunction in a general population. *Circ Heart Fail* 2009;2:105–12.
8. Yu J, Oh PC, Kim M, et al. Improved early risk stratification of patients with ST-segment

- 1  
2  
3  
4 1 elevation myocardial infarction undergoing primary percutaneous coronary intervention  
5  
6 2 using a combination of serum soluble ST2 and NT-proBNP. *PLoS One* 2017;12:e0182829.  
7  
8  
9 3 9. Hall C. Essential biochemistry and physiology of (NT-pro) BNP. *Eur J Heart Fail*  
10  
11 4 2004;6:257–60.  
12  
13 5 10. Coats CJ, Parisi V, Ramos M, et al. Role of serum N-terminal pro-brain natriuretic peptide  
14  
15 6 measurement in diagnosis of cardiac involvement in patients with Anderson-Fabry disease.  
16  
17 7 *Am J Cardiol* 2013;111:111–7.  
18  
19 8 11. Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart failure: a  
20  
21 9 consensus statement on the diagnosis of heart failure with normal left ventricular ejection  
22  
23 10 fraction by the Heart Failure and Echocardiography Associations of the European Society  
24  
25 11 of Cardiology. *Eur Heart J* 2007;28:2539–50.  
26  
27 12 12. Gehle P, Robinson PN, Heinzl F, et al. NT-proBNP and diastolic left ventricular function  
28  
29 13 in patients with Marfan syndrome. *Int J Cardiol Heart Vasc* 2016;12:15–20.  
30  
31 14 13. Folland ED, Parisi AF, Moynihan PF, et al. Assessment of left ventricular ejection fraction  
32  
33 15 and volumes by real-time, two-dimensional echocardiography. A comparison of  
34  
35 16 cineangiographic and radionuclide techniques. *Circulation* 1979;60:760-6.  
36  
37 17 14. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber  
38  
39 18 quantification by echocardiography in adults: an update from the American Society of  
40  
41 19 Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J*  
42  
43 20 *Cardiovasc Imaging* 2015;16:233–71.  
44  
45 21 15. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left  
46  
47 22 ventricular diastolic function by echocardiography: an update from the American Society  
48  
49 23 of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc*  
50  
51 24 *Echocardiogr* 2016;29:277–314.  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 1 16. Kane GC, Karon BL, Mahoney DW, et al. Progression of left ventricular diastolic  
5  
6 2 dysfunction and risk of heart failure. *JAMA* 2011;306:856–63.  
7  
8  
9 3 17. From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes  
10  
11 4 mellitus and pre-clinical diastolic dysfunction: a population-based study. *J Am Coll Cardiol*  
12  
13 5 2010;55:300–5.  
14  
15  
16 6 18. Ren X, Ristow B, Na B, et al. Prevalence and prognosis of asymptomatic left ventricular  
17  
18 7 diastolic dysfunction in ambulatory patients with coronary heart disease. *Am J Cardiol*  
19  
20 8 2007;99:1643–7.  
21  
22  
23 9 19 Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and diastolic ventricular  
24  
25 10 dysfunction in the community: appreciating the scope of the heart failure epidemic. *JAMA*  
26  
27 11 2003;289:194–202.  
28  
29  
30 12 20. Mueller T, Gegenhuber A, Poelz W, et al. Comparison of the Biomedica NT-proBNP  
31  
32 13 enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay:  
33  
34 14 implications for the prediction of symptomatic and asymptomatic structural heart disease.  
35  
36 15 *Clin Chem* 2003;49:976–9.  
37  
38  
39 16 21. Hung TC, Wang KT, Yun CH, et al. Value of serum N-terminal B-type natriuretic peptide  
40  
41 17 in asymptomatic structural heart disease in Taiwanese population: Comparisons with  
42  
43 18 current ESC Guidelines. *Int J Cardiol* 2017;231:195–200.  
44  
45  
46 19 22. Abhayaratna WP, Marwick TH, Smith WT, et al. Characteristics of left ventricular diastolic  
47  
48 20 dysfunction in the community: an echocardiographic survey. *Heart* 2006;92:1259–64.  
49  
50  
51 21 23. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management  
52  
53 22 of heart failure: a report of the American College of Cardiology Foundation/American  
54  
55 23 Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2013;62:e147–  
56  
57 24 239.  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

3 Table 1 Characteristics of study subjects according to the presence of structural abnormalities

Variables	No Structural abnormality	Structural abnormality	P Value
	(N=560)	(N=92)	
Age (year)	57.7 ± 8.9	60.8 ± 8.8	0.017
Gender Male, N (%)	309 (55.2)	52 (56.5)	0.432
BMI (kg/m <sup>2</sup> )	24.2 ± 3.0	26.9 ± 3.5	<0.001
SBP (mmHg)	119.8 ± 13.7	126.6 ± 12.1	<0.001
DBP (mmHg)	73.7 ± 8.9	76.9 ± 8.6	0.003
Hb (g/L)	147.7 ± 14.6	146.3 ± 16.5	0.965
FBS (mmol/L)	5.9 ± 1.5	6.2 ± 1.5	0.289
TC (mmol/L)	5.4 ± 1.1	5.2 ± 1.0	0.110
TG (mmol/L)	1.4 ± 0.9	1.6 ± 1.1	0.125
HDL-C (mmol/L)	1.5 ± 0.4	1.4 ± 0.4	<0.001
LDL-C (mmol/L)	3.2 ± 1	3.1 ± 0.9	0.236
Creatinine (µmol/L)	78.5 ± 15.2	76.9 ± 15.7	0.520
eGFR (mL/min/1.73m <sup>2</sup> )	85.3 ± 14.7	87.3 ± 18.4	0.639
NT-proBNP (pg/mL)	29.6 ± 27.5	55.8 ± 91.5	0.015
LVEF (%)	66 ± 6.5	64.9 ± 7.3	0.807
LVMI (g/m <sup>2</sup> )	71.7 ± 13.3	88.9 ± 18.1	<0.001
LAD (mL/m <sup>2</sup> )	33.7 ± 3.9	40.8 ± 5.5	<0.001
E/e'	11 ± 3.4	13 ± 3.5	0.002
e' (cm/s)	6.2 ± 1.6	5.9 ± 5.4	0.950

4 Continuous variables are expressed as mean±SD values and were compared using Student's *t*-test.  
5 Categorical variables are expressed as N (%) values and were analyzed using the chi-square test.  
6 NT-proBNP, N-terminal pro-B-type natriuretic peptide; BMI, body mass index; SBP, systolic blood  
7 pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglyceride; HDL-C, HDL-

1 cholesterol; LDL-C, LDL-cholesterol; FBS, fasting blood sugar; LVEF, left ventricular ejection fraction;  
 2 LVMI, left ventricular mass index; LAD, left atrial dimension; E/e', early diastolic mitral inflow  
 3 velocity/early diastolic mitral annular velocity; e', mean e' septal and lateral wall velocity.  
 4

5 Table 2 Characteristics of study subjects according to the presence of diastolic dysfunction

Variables	No diastolic dysfunction	Diastolic dysfunction	P Value
	(N=182)	(N=470)	
Age (year)	52.6 ± 8.8	60.3 ± 8.1	<0.001
Gender Male, N (%)	93 (51.1)	268 (57.0)	0.172
BMI (kg/m <sup>2</sup> )	23.4 ± 3	25 ± 3.2	<0.001
SBP (mmHg)	116.2 ± 12.6	122.6 ± 13.7	<0.001
DBP (mmHg)	71.4 ± 8.6	75.3 ± 8.8	<0.001
Hb (g/L)	144 ± 15.2	148.9 ± 14.5	<0.001
FBS (mmol/L)	5.6 ± 1	6.1 ± 1.6	<0.001
TC (mmol/L)	5.4 ± 1	5.4 ± 1.1	0.958
TG (mmol/L)	1.2 ± 0.8	1.5 ± 1	<0.001
HDL-C (mmol/L)	1.6 ± 0.4	1.5 ± 0.4	<0.001
LDL-C (mmol/L)	3.2 ± 1	3.2 ± 1	0.996
Creatinine (µmol/L)	76.3 ± 15.5	79 ± 15.2	0.040
eGFR (mL/min/1.73m <sup>2</sup> )	88.9 ± 15.7	84.3 ± 15	0.001
NT-proBNP (pg/mL)	35.9 ± 63.5	32.3 ± 32.9	0.476
LVEF (%)	65.2 ± 6.9	66.1 ± 6.5	0.131
LVMI (g/m <sup>2</sup> )	69.5 ± 14.2	75.9 ± 15.3	<0.001
LAD (mL/m <sup>2</sup> )	33.9 ± 5.1	35 ± 4.7	0.007
E/e'	9.4 ± 2.1	12 ± 3.6	<0.001
e' (cm/s)	8.4 ± 3.6	5.3 ± 1	<0.001

6 Continuous variables are expressed as mean±SD values and were compared using Student's *t*-test.  
 7 Categorical variables are expressed as N (%) values and were analyzed using the chi-square test.  
 8 NT-proBNP, N-terminal pro-B-type natriuretic peptide; BMI, body mass index; SBP, systolic blood  
 9 pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglyceride; HDL-C, HDL-



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 cholesterol; LDL-C, LDL-cholesterol; FBS, fasting blood sugar; LVEF, left ventricular ejection fraction;  
2 LVMI, left ventricular mass index; LAD, left atrial dimension; E/e', early diastolic mitral inflow  
3 velocity/early diastolic mitral annular velocity; e', mean e' septal and lateral wall velocity.

For peer review only

1 Table 3 Characteristics of study subjects according to the presence of structural abnormalities and/or diastolic dysfunction

Variables	Normal <sup>a</sup>		Structural abnormality <sup>b</sup>		Diastolic dysfunction <sup>c</sup>		Structural abnormality & Diastolic dysfunction <sup>d</sup>		P-Value	Multiple comparison
	(N=167)		(N=15)		(N=393)		(N=77)			
Age (year)	52.5	± 8.8	54.8	± 8.9	59.9	± 8	62	± 8.3	<0.001	a,b < c,d
Gender Male, N (%)	82	(49.1)	11	(73.3)	227	(57.8)	41	(53.3)	0.129	-
BMI (kg/m <sup>2</sup> )	23.2	± 3	25.9	± 2.1	24.6	± 2.9	27.1	± 3.7	<0.001	a < d
SBP (mmHg)	115.7	± 12.6	121.3	± 11.5	121.6	± 13.8	127.6	± 12	<0.001	a < d
DBP (mmHg)	71.2	± 8.7	73	± 8	74.8	± 8.8	77.6	± 8.5	<0.001	a,b < d
Hb (g/L)	143.7	± 15.1	147.3	± 16.6	149.4	± 14.1	146.1	± 16.6	<0.001	-
FBS (mmol/L)	5.6	± 1	5.5	± 1	6.1	± 1.6	6.4	± 1.5	<0.001	b < d
TC (mmol/L)	5.4	± 1	5.1	± 1.3	5.4	± 1.1	5.3	± 0.9	0.631	-
TG (mmol/L)	1.2	± 0.8	0.9	± 0.7	1.4	± 1	1.7	± 1.1	<0.001	b < d
HDL-C (mmol/L)	1.6	± 0.4	1.5	± 0.5	1.5	± 0.4	1.4	± 0.4	0.001	a > d
LDL-C (mmol/L)	3.2	± 1	3.2	± 1	3.3	± 1	3.1	± 0.9	0.618	-
Creatinine (µmol/L)	75.4	± 15.1	85.5	± 18.2	79.7	± 15.2	75.2	± 14.7	0.001	a,d < b
eGFR (mL/min/1.73m <sup>2</sup> )†	89.5	± 15.8	82.3	± 13.1	83.5	± 13.9	88.3	± 19.2	<0.001	b < a
NT-proBNP (pg/mL)†	27.1	± 16	132.9	± 195.2	30.7	± 31.1	40.8	± 40	0.005	a,c,d < b
LVEF (%)†	65.3	± 6.3	63.8	± 12	66.3	± 6.6	65.2	± 6.2	0.272	-
LVMI (g/m <sup>2</sup> )†	67.8	± 12.8	88	± 16.2	73.3	± 13.1	89.1	± 18.5	<0.001	a,c < b,d
LAD (mL/m <sup>2</sup> )†	33	± 3.9	43.5	± 6.2	34	± 3.8	40.2	± 5.2	<0.001	a,c < d < b
E/e'†	9.3	± 2.1	10.7	± 2.4	11.8	± 3.5	13.4	± 3.5	<0.001	a < b,c < d
e' (cm/s)†	8.2	± 1.1	11	± 12.3	5.4	± 0.9	4.9	± 1.2	<0.001	d,c < a < b

2 †Welch's ANOVA (not equal variance) was used.

3 NT-proBNP, N-terminal pro-B-type natriuretic peptide; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total  
 4 cholesterol; TG, triglyceride; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; FBS, fasting blood sugar; LVEF, left ventricular ejection fraction;  
 5 LVMI, left ventricular mass index; LAD, left atrial dimension; E/e', early diastolic mitral inflow velocity/early diastolic mitral annular velocity; e', mean  
 6 e' septal and lateral wall velocity.

1 Table 4 Regression analysis of the variables affecting an increased NT-proBNP level

Variables	Univariate model				Multivariate model							
					Model 1				Model 2			
	Coeff.*	95% CI	P-value	R <sup>2</sup>	Coeff.*	95% CI	P-value	R <sup>2</sup>	Coeff.*	95% CI	P-value	R <sup>2</sup>
Age (year)	0.97	(0.6–1.33)	<0.001	0.040	0.58	(0.15– 1.01)	0.008	0.153	0.51	(0.13– 0.89)	0.009	0.140
Sex (ref: female)	-0.52	(-7.27– 6.23)	0.879	<0.001	-17.31	(-28.12– -6.51)	0.002		-19.47	(-28.5– -10.45)	<0.001	
BMI (kg/m <sup>2</sup> )	-0.26	(-1.3– 0.78)	0.626	<0.001	-1.97	(-3.2 – -0.74)	0.002		-2.34	(-3.47– -1.21)	<0.001	
SBP (mmHg)	0.14	(-0.1–0.39)	0.258	0.002	-0.25	(-0.61– 0.1)	0.165					
DBP (mmHg)	0.27	(-0.11– 0.64)	0.164	0.003	0.48	(-0.06– 1.01)	0.081					
Hb (g/L)	-0.14	(-0.37– 0.08)	0.216	0.002	-0.15	(-0.45– 0.15)	0.338					
FBS (mmol/L)	-0.97	(-3.22– 1.28)	0.396	0.001	-0.44	(-2.71– 1.84)	0.707					
TG (mmol/L)	-2.34	(-5.81– 1.13)	0.186	0.003	-2.01	(-5.8– 1.78)	0.298					
HDL-C (mmol/L)	-1.72	(-10.2– 6.77)	0.691	<0.001	-0.76	(-9.82– 8.31)	0.870					
LDL-C (mmol/L)	-3.62	(-6.96– -0.27)	0.034	0.007	-2.95	(-6.2– 0.3)	0.075					
Creatinine (µmol/L)	0.36	(0.14– 0.58)	0.001	0.016	0.70	(0.4– 0.99)	<0.001		0.68	(0.4 –0.97)	<0.001	
LVEF (%)	-0.01	(-0.51– 0.49)	0.968	<0.001	0.12	(-0.37– 0.6)	0.637					
LVMI (g/m <sup>2</sup> )	0.47	(0.26– 0.69)	<0.001	0.028	0.28	(0.04– 0.52)	0.022		0.30	(0.07– 0.53)	0.012	
LAD (mL/m <sup>2</sup> )	2.11	(1.43– 2.79)	<0.001	0.054	2.58	(1.79– 3.37)	<0.001		2.63	(1.85– 3.41)	<0.001	
E/e'	0.65	(-0.33– 1.63)	0.191	0.003	-0.14	(-1.24– 0.97)	0.806					
e' (cm/s)	-0.54	(-1.87– 0.8)	0.430	0.001	0.38	(-1.04– 1.81)	0.597					

2 \*Regression coefficient: the usual interpretation of a regression coefficient is the average change in the outcome variable when the corresponding predictor  
3 variable is changed by one unit.

4 Model 1: adjust for age, sex, BMI, blood pressure, Hb, FBS, blood lipid creatinine

5 Model 2: adjusted for age, sex, BMI, creatinine, LVMI, and LAD

6 NT-proBNP, N-terminal pro-B-type natriuretic peptide; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total  
7 cholesterol; TG, triglyceride; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; FBS, fasting blood sugar; LVEF, left ventricular ejection fraction; LVMI,  
8 left ventricular mass index; LAD, left atrial dimension; E/e', early diastolic mitral inflow velocity/early diastolic mitral annular velocity; e', mean e' septal  
9 and lateral wall velocity.




Figure 1 Study flow diagram.

196x95mm (96 x 96 DPI)




Figure 2 N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels according to sex and age categories. Box limits and horizontal lines within boxes represent interquartile ranges and the median, respectively. The upper and lower whiskers indicate the 97.5th and 2.5th percentiles, respectively.

144x102mm (96 x 96 DPI)




Figure 3 N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels of subjects with and without structural abnormalities according to age categories. Box limits and horizontal lines within boxes represent interquartile ranges and the median, respectively. The upper and lower whiskers indicate the 97.5th and 2.5th percentiles, respectively.

145x95mm (96 x 96 DPI)




Figure 4 Receiver operating characteristic curve and cutoff value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in predicting cardiac structural abnormalities.

106x101mm (96 x 96 DPI)

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Title
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	3
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	4
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5,6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5,6
Bias	9	Describe any efforts to address potential sources of bias	Not relevant
Study size	10	Explain how the study size was arrived at	10
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5,6
		(b) Describe any methods used to examine subgroups and interactions	5,6
		(c) Explain how missing data were addressed	Not relevant
		(d) If applicable, describe analytical methods taking account of sampling strategy	Not relevant
		(e) Describe any sensitivity analyses	No
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Not relevant
		(b) Give reasons for non-participation at each stage	Not relevant
		(c) Consider use of a flow diagram	Not relevant
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	Not relevant
Outcome data	15*	Report numbers of outcome events or summary measures	7,8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make	Not relevant



		clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	Not relevant
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not relevant
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Not relevant
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	9-11
Generalisability	21	Discuss the generalisability (external validity) of the study results	9
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).